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ABSTRACT 
 
 
X-rays have been used for non-invasive high-resolution imaging of thick 
biological specimens since their discovery in 1895. They are widely used for 
structural imaging of bone, metal implants, and cavities in soft tissue. Recently, a 
number of new contrast methodologies have emerged which are expanding X-
ray’s biomedical applications to functional as well as structural imaging. However, 
traditional X-ray imaging provides high spatial resolution imaging through tissue 
but do not measure chemical concentrations. In this dissertation, we describe an 
X-ray excited optical luminescence (XEOL) technique which uses a scanning X-
ray beam to irradiate Gd2O2S phosphors and detect the resulting visible 
luminescence through the tissue.  The amount of light collected is modulated by 
optical absorption in close proximity to the luminescence source. The ability to 
specifically target biological processes in vivo makes nanophosphors 
promising molecular imaging agents for XEOL. We also describe versatile 
techniques to design and fabricate multifunctional X-ray nanophosphors. The 
addition of pH-triggred drug release on our X-ray nanophosphors make it 
possible to monitor pH-triggered drug release rate in real time. The iron oxide 
encapsulated X-ray nanosctintillators offer promising multimodal 
MRI/fluorescence/X-ray luminescence contrast agents.  
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concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. 
Group C: T2-weighted images of hollow nanorice with concentration 
of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group A*: T2-
weighted images of nanorice with concentration of 0.8 mg/ml, 0.4 
mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B*: T2*-weighted images 
of nanoeyes with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, 
and 0.05 mg/ml. Group C*: T2-weighted images of hollow nanorice 
with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 
mg/ml. Reproduced from Ref. 125 with permission from the Royal 
Society of Chemistry.................................................................................. 113 
 
 5.14 The relaxation rate curves as a function of concentration. ■ : nanorice, 
▲: nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h),   
●: hollow nanorice. Error bars represent the standard deviation.                   
Reproduced from Ref. 125 with permission from the Royal Society of 
Chemistry.. ................................................................................................. 114 
 
 5.15 The relaxation rate curves, 1/T2*, as a function of particle 
concentration. To calculate relaxivity, r2*, the curve is fit to a straight 
line for concentrations up to 0.4 mg/mL) ■ : nanorice, ▲: nanoeyes 
(iron oxide core was incubated in oxalic acid for 9.5 h),  ●: hollow 
nanorice. Reproduced from Ref. 125 with permission from the Royal 
Society of Chemistry.................................................................................. 115 
 
 5.16 Cytotoxicity test for hollow nanorice (Gd2O3:Eu). Reproduced from 
Ref. 125 with permission from the Royal Society of Chemistry.. ............. 119 
  
 
 
CHAPTER ONE 
I. X-RAY PHOSPHORS AND THEIR APPLICATIONS 
Discovery of X-ray phosphors 
            X-rays are electromagnetic wave with shorter wavelength (<10 nm) than the 
infrared, visible, or ultraviolet light. They are widely used since they were discovered in 
1895 by Wilhelm Conrad Roentgen.
1-2
 The research started immediately to find materials 
capable of converting X-ray to visible light.   These materials were later named X-ray 
phosphors (sometimes referred to as scintillators). CaWO4 powder discovered in 1896 by 
Pupin was used more than 75 years. A few years later, Crookes and Regener found the 
ZnS based phosphors. The excitation energy for X-ray phosphors is X-ray which is 
different from the energy sources for photoluminescent and electroluminescent 
phosphors. The energy sources for photo-luminescent and electroluminescent phosphors 
are visible or ultraviolet light and electrons, respectively. 
 
Principle of conversion of X-ray to visible light in X-ray phosphors 
            The conversion of X-ray to visible light mainly can be divided into three steps 
(Figure 1.1). The first step involves multistep interaction of X-ray with the lattice of the 
phosphor or absorption of X-ray by the phosphors via the Compton and photoelectric 
effect. In this step, plenty of electron hole pairs are generated in the conduction bands and 
thermalized in the valence bands. In the second step, electron hole pairs transport through 
the crystal lattice. The last step consists in electron hole pair trapping by the luminescent 
centers (doping ions) and their radioactive combination. 
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Figure 1.1 Schematic illustration of the three steps for the X-ray conversion to visible 
light. 
 
Characterization of X-ray phosphors 
               X-ray phosphors are often used in X-ray imaging screens and films for 
projection imaging, fluoroscopy, and CT to convert X-ray image into light. Their most 
considered characteristics are the photon-conversion efficiency, luminescence decay 
time, and chemical stability. The total number of visible light photons emitted by X-ray 
phosphors under 1 keV X-ray is called photon conversion efficiency or light yield. The 
fundamental limit of the light yield (Y) of an activated phosphor (photons emitted/MeV) 
is determined by the band gap Egap (eV) of the host material and is approximately given 
by equation (1) with a maximum of close to 40% energy efficiency.
3
  
 3 
  
   
       
                  (1) 
              The fundamental limit on light output for various phosphors. The fundamental 
limit is smallest for fluorides with the largest band gap and the limit is largest for sulfides 
with small band gaps. The decay rate of the luminescence center is determined by its 
transition dipole moment from the excited to ground state. For most of the rare earth ions, 
the decay times usually in the order of μs to ms. The chemical stability is crucial for the 
phosphors especially hygroscopic materials in practical use because the hygroscopicity 
limits the long term operation of these phosphors in open air.  It also limits the 
applications of these particles in physiological conditions which will discuss later in the 
X-ray excited optical luminescence technique.  
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Table 1.1 Examples of X-ray phosphors. Reproduced from Ref. 124 with permission from 
the PCCP Owner Societies. 
Phosphor Decay 
time (ns) 
Maximum Emission 
Wavelength (nm) 
Conversion efficiency 
(visible photons/MeV) 
Hygroscopicity Density g/cm3 Reference 
CsI:Tl 800 550 66,000 Yes 4.51 4-6 
CsI:Na 630 425 49,000 Yes 4.51 7-8 
NaI:Tl 230 415 44,000 Yes 3.67 4-5, 8 
LiI:Eu 1,200 475 15,000 Yes 4.08 9-10 
LaBr3:Ce 35 358 61,000 Yes 5.3 11 
K2LaI5: Ce 24 420 55,000 Yes 4.4 12 
CaF2:Eu ~1,000 435 24,000 No 3.18 4, 13 
SrI2:Ce,Na 27 (25%), 
450 (75%) 
404 16,000 Yes 4.59 14 
SrI2:Eu 1,200 435 120,000 Yes 4.59 14 
BaFBr:Eu 800 390 60,000 Yes 4.56 15-16 
LaOBr:Tb ~1000,000 425 67,000 Yes 6.3 1, 17 
LaOBr:Tm ~1000,000 374, 472 6,0000 Yes 6.1 18 
ZnS:Ag 1,200 450 49,000 No 3.9 19 
M’-YTaO4 3,000 337 40,000 No 7.5 16, 18 
M’-YTaO4:Nb ~2,000 410 40,000 No 7.5 20-21 
BaHfO3:Ce 25 400 40,000 No 8.5 1, 22 
Bi4Ge3O12 (BGO) 300 480 9,000 No 7.1 4, 23 
CaWO4 8,000 425 15,800 No 6.1 24-25 
CdWO4 5,000 495 20,000 No 7.9 26 
YAlO3:Ce 24 360 20,100 No 5.35 27-28 
Y3Al5O12:Ce 90~120 550 16,700 No 4.55 4-5, 29 
LuAlO3:Ce 18 365 12,000 No 8.34 1, 30 
Lu3Al5O12:Ce 55 530 12,500 No 6.7 31-32 
Lu2SiO5:Ce 30 425 33,000 No 7.4 33 
Lu2O3:Tb,Eu ~1,000 612 30,000 No 9.4 34 
Gd2O3:Eu ~1,000 612 40,000 No 5.91 15, 35 
Gd2O2S:Eu ~1000,000 623 60,000 No 7.3 36 
Gd2O2S:Tb ~1000,000 545 60,000 No 7.3 22 
Gd2O2S:Pr,Ce,F 3,000 510 48,000 No 7.3 22 
Gd3Ga5O12:Cr,Ce 140,000 730 40,000 No 7.1 21, 37 
Gd2SiO5:Ce 60 430 8,000 No 6.7 38-39 
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         Discovered in 1896, CaWO4, was used for the next 80 years in X-ray phosphor 
screens due to its reasonable X-ray absorption in the 20-100 keV range and blue 
emission.
40
 However, CaWO4 suffers from low conversion efficiency (only 15,000 
optical photons /Mev). Currently, alkali metal halides containing small amounts of 
activator such as NaI:Tl and CsI:Tl are being widely used because of their superior 
conversion efficiency (64,000 optical photons/MeV for CsI:Tl). However, most alkali 
metal halides are hygroscopic requiring that the phosphors be kept moisture-free. 
Recently, optical ceramic phosphors have become popular due to their light conversion 
efficiency and chemical stability. Bismuth germanate oxide (BGO), a ceramic 
scinitillator, is often used due to its rapid response and little or no afterglow. The speed of 
response and high density make the phosphor ideal for high energy and high acquisition 
rate X-ray measurements. BGO is not hygroscopic, however, its low conversion 
efficiency (only 9,000 optical photons /Mev) results in poorer energy resolution than 
detectors based on alkali metal halides. Rare earth oxysulfide phosphors (M2O2S:Ln, M= 
Gd or Y. Ln= Ce, Pr, Eu, Tm, or Tb) are a promising class of ceramic scinitillators with 
improved absorption, greater density and higher X-ray to light conversion efficiency 
(60,000 optical photons/Mev). 
 
X-ray luminescence tomography (XLT)  
             Though the aforementioned phosphors discussed are typically used in projection 
X-ray imaging and computed tomography (CT), phosphor particles with sizes ranging 
from nanometers to micrometers are used as contrast agents for X-ray luminescence 
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tomography (XLT).
41-42
 The basic principle of XLT is based on luminescence 
measurements from selectively excited nanophosphors, it’s a hybrid technique as a 
complementary to CT. XLT usually collects signal in physiological or mimic 
physiological environment. Although alkali metal halides containing small amounts of 
activator such as NaI:Tl and CsI:Tl have great photo conversion efficiency, but they 
suffer from hygroscopicity and can dissolve in physiological environment readily. 
Recently, rare-earth doped oxide and oxysulfide nanoparticles have been investigated as 
labels for low-background imaging using up-conversion,
43
 radioluminescence,
18, 40
 long-
lifetime phosphorescence,
44-45
 and proximity scintillation assays. These nanoparticles are 
attractive imaging agents due to their chemical stability, photostability, large X-ray 
absorption cross-section and scintillation efficiency, and relatively low toxicity, 
especially after silica encapsulation.
46
 X-ray phosphors may also be coupled to 
photodynamic nanoparticles to enhance reactive oxygen production,
47
 although their 
effectiveness depends greatly upon their ability to target the reactive oxygen damage to 
the nucleus or other sensitive sites.
48
  
            Through the use of a scanning luminescence X-ray microscope, Morrone 
imaged the optical emission of terbium labeled actin in a single cell to obtain ~50 nm 
resolution based on the selective excitation of lanthanide organo-polychelate 
complexes and optical detection of their luminescence.
49
 The high resolution of this 
technique lies in the fact that the X-ray excited  luminescence is only produced in the 
path of the narrow scanning X-ray beam. However, this small voxel size and weak 
scintillation yield necessitated the use of a very intense X-ray dose exceeding 10
8
 Gy. 
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To increase the scintillation efficiency, Adam and coworkers proposed using quantum 
dots for multiplexed cell labeling.
50
 Alternative optical microscopy techniques have 
been developed for near-field imaging in the absence of light scattering.
51-53
 However, 
the principle of scanning X-ray excitation can also be applied to imaging in tissues 
thicker than 1 mm where optical scattering prevents high-resolution optical imaging.  
            In order to detect a wider variety of analytes with molecular information, X-
ray excited optical luminescence (XEOL) based techniques were recently developed 
with lower backgrounds and lower X-ray doses. With a 1 mm X-ray beam and 1~100 
cGy radiation dose, Pratx et al. developed X-ray luminescence computed tomography 
(XLCT) and achieved a spatial resolution of 1 mm through tissue-mimicking 
material.
54
 X-ray phosphors are a series of materials that convert X-ray photons to 
visible photons when excited by an X-ray source. XLCT is similar to XFCT in its 
sample irradiation method, however,  XLCT uses photodetectors to capture the optical 
photons emitted from the nanophosphors rather than an X-ray spectrometer for 
secondary fluorescent X-ray detection. Because the X-ray does not scatter much in 
tissue and the X-ray luminescence is only generated on the path of the narrow X-ray 
beam, the optical detector need not spatially resolve the source of luminescence. As 
long as the luminesence can be detected,  the spatial resolution is defined by the 
narrow X-ray beam. The advantages of this technique are its combination of high 
sensitivity of radioluminescent nanoparticles and the high spatial localization of 
collimated X-ray beams. Pratx and coworkers recently used XLCT to image the cross 
sectional distribution of microsize phosphor particles in 4.5 cm of an agar tissue 
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phantom.
41
 Carpenter recently completed a numerical phantom experiment to simulate 
the X-ray dose (Gy) required to achieve a signal-to-noise ratio of 10 for varying 
concentrations. They found that picomolar (ng/ml) concentrations of 10 nm X-ray 
phosphor are detectable for a mammographic-like dose.
55
 They have also shown that 
X-ray luminescence can be observed in small animal models.
54-55
  
               Although high resolution was demonstrated using XLCT, the image is 
acquired slowly by scanning the X-ray beam through the sample and rotating the 
sample through 180º. In addition, there are applications such as tumor-resection 
where the X-ray excitation angle is limited by geometry, and where increased rapid 
acquisition is critical. Limited-angle X-ray luminescence tomography was deveoped 
to address these applications based on a hybrid X-ray/optical reconstruction, which 
allows XLCT spatial encoding in a limited-angle geometry, and diffuse optical spatial 
discrimination for the remaining dimensions. According to the model, µg·mL
-1
 
particle concentrations may be observed through 5 cm of tissue with ~10 mGy doses. 
The limited angle technique is expected to be especially useful  in surgical 
applicaions such as breast or brain excision due to rapid acquisition speed, convenient 
geometric configuration, high depth resolution, and low X-ray dose.
56
  
                X-ray excited optical luminescence (XEOL) can be used not only to locate X-
ray phosphors in tissue, but also serve as a local light source for fluorescent and 
colorimetric chemical indicators. Though optical microscopy (e.g. scanning confocal 
microscopy) is an excellent technique for biomedical imaging, it has limited utility in 
tissues deeper than 1 mm because almost all light is scattered, resulting in poor 
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resolution.
48, 57-58
 The ability to specifically target biological processes in vivo makes 
nanoparticles promising molecular imaging agents for X-ray excited optical 
luminescence techniques. There is a urgent need of novel X-ray nanophosphors for 
XEOL. However, the tranditional solid reaction methods can only provide mircosize 
or even bigger size particles.
18
 While the commonly used coprecipiation of host 
material and doping ions by urea decomposition offers nanosized particles, most of 
the work just focus on the particles synthesis and characterization.
59
 Less works have 
been reported on the synthesis of multifunctional X-ray nanophosphors for the 
chemical imaging though tissue or in vivo study.
60
  
            This chapter has introduced the histrical discovery, mechanism of conversion 
of X-rays to visible light, important characterization parameters of X-ray phosphor. 
Some of the important X-ray phosphors and their characterics are also included. The 
tranditional application of X-ray phosphors mainly in the X-ray detection and CT 
screen. With the developmet of XLCT, the synthesis and applicaons in deep tissue 
imaging or chemical detection of X-ray phosphors with nanosize attract a lot of 
attention in the past decades.  
            Chapter II describes a novel method for high-resolution chemical imaging on 
a surface embedded in tissue. The sensor surface consists of an X-ray scintillator film 
coated in a thin film loaded with chemical indicator dye. A narrow scanning X-ray 
beam is usedd to excite luminescence from X-ray phosphors located within the beam. 
This luminescence passs through the indicator film, and the spectrum is analyzed to 
measure chemical concentrations at that location. A pH sensor is demonstrated with a 
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dynamic range between pH 6 to 9 and noise level of 0.05 pH units using methyl-red 
dyed pH paper. The location of the interface between two types of phosphor films is 
obtained with 0.30 mm spatial resolution even though the images are highly blurred 
by 10 mm of chicken breast. This work has important applications for detecting pH 
changes on surfaces of implanted medical devices. 
            Chapter III reports a high-spatial resolution imaging technique to measure 
optical absorption and detect chemical and physical changes on surfaces embedded in 
thick tissue. Developing sensors to measure chemical concentrations on implanted 
surfaces through tissue is an important challenge for analytical chemistry and 
biomedical imaging. Tissue scattering dramatically reduces the resolution of optical 
imaging. In contrast, X-rays provide high spatial resolution imaging through tissue 
but do not measure chemical concentrations. We describe a hybrid technique which 
uses a scanning X-ray beam to irradiate Gd2O2S scintillators and detect the resulting 
visible luminescence through the tissue. The amount of light collected is modulated 
by optical absorption in close proximity to the luminescence source. By scanning the 
X-ray beam, and measuring total amount of light collected, one can measure the local 
absorption near scintillators at a resolution limited by the width of luminescence 
source (i.e. the width of the X-ray excitation beam). For proof of principle, a 
rectangular 1.7 mm scanning X-ray beam was used to excite a single layer of 8 μm 
Gd2O2S particles, and detect the absorption of 5 nm thick silver island film through 
10 mm of pork. Lifetime and spectroscopic measurements, as well changing the 
refractive index of the surroundings indicate that the silver reduces the optical signal 
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through attenuated total internal reflection. The technique was used to image the 
dissolution of regions of the silver island film which were exposed to 1 mM of H2O2 
through 1 cm of pork tissue. 
            Chapter IV explores a significant and novel theranostic nanotechnology that 
combines multimodal imaging with drug delivery. One of the greatest challenges in 
cancer therapy is to develop methods to deliver chemotherapy agents to tumor cells while 
reducing systemic toxicity to non-cancerous cells. A promising approach to localizing 
drug release is to employ drug-loaded nanoparticles with coatings that release the drugs 
only in the presence of specific triggers found in the target cells such as pH, enzymes, or 
light. However, many parameters affect the nanoparticle distribution and drug release rate 
and it is difficult to quantify drug release in situ.  In this work, we show proof-of-
principle for a “smart” radioluminescent nanocapsule with X-ray excited optical 
luminescence (XEOL) spectrum that changes during release of the optically absorbing 
chemotherapy drug, doxorubicin. XEOL provides an almost background-free luminescent 
signal for measuring drug release from particles irradiated by a narrow X-ray beam. We 
study in vitro pH triggered release rates of doxorubicin from nanocapsules coated with a 
pH responsive polyelectrolyte multilayer using HPLC and XEOL spectroscopy. The 
doxorubicin was loaded to over 5 % by weight, and released from the capsule with a time 
constant in vitro of ~ 36 days at pH 7.4, and 21.4 hr at pH 5.0, respectively. The 
Gd2O2S:Eu nanocapsules are also paramagnetic at room temperature with similar 
magnetic susceptibility and similarly good MRI T2 relaxivities to Gd2O3, but the sulfur 
increases the radioluminescence intensity and shifts the spectrum. Empty nanocapsules 
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did not affect cell viability up to concentrations of at least 250 µg/ml. These empty 
nanocapsules accumulated in a mouse liver and spleen following tail vein injection, and 
could be observed in vivo using XEOL. The particles are synthesized with a versatile 
template synthesis technique which allows for control of particle size and shape. The 
XEOL analysis technique opens the door to non-invasive quantification of drug release as 
a function of nanoparticle size, shape, surface chemistry and tissue type. 
            Chapter V provides a mutifunctiaonl magnetic luminescent particles by 
partially etching and homogenous luminescent material coating method. When X-rays 
irradiate these radioluminescence nanoparticles, they generate visible and near infrared 
light that can penetrate through centimeters of tissue. X-ray luminescence tomography 
(XLT) maps the location of these radioluminescent contrast agents at high resolution by 
scanning a narrow X-ray beam through the tissue sample and collecting the luminescence 
at every position. Adding magnetic functionality to these radioluminescent particles 
would enable them to be guided, oriented, and heated using external magnetic fields, 
while their location and spectrum could be imaged with XLT and complementary 
magnetic resonance imaging. In this work, multifunctional monodispersed magnetic 
radioluminescent nanoparticles were developed as potential drug delivery carriers and 
radioluminescence imaging agents. The particles consisted of a spindle-shaped magnetic 
γ-Fe2O3 core and a radioluminescent europium-doped gadolinium oxide shell. Particles 
with solid iron oxide cores displayed saturation magnetizations consistent with their 13% 
core volume, however, the iron oxide quenched their luminescence. In order to increase 
the luminescence, we partially etched the iron oxide core in oxalic acid while preserving 
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the radioluminescent shell. The core size was controlled by the etching time which in turn 
affected the particles' luminescence and magnetic properties. Particles with intermediate 
core sizes displayed both strong magnetophoresis and luminescence properties. They also 
served as MRI contrast agents with relaxivities of up to 58 mM
−1
 s
−1
 (r2) and 120 mM
−1
 
s
−1
 (r2*). These particles offer promising multimodal MRI/fluorescence/X-ray 
luminescence contrast agents. Our core–shell synthesis technique offers a flexible method 
to control particle size, shape, and composition for a wide range of biological 
applications of magnetic/luminescent nanoparticles. 
            Chapter VI summarizes the work in this dissertation and also includes the 
future directions. 
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                                                               CHAPTTER TWO 
II. HIGH-RESOLUTION CHEMICAL IMAGING THROUGH TISSUE WITH AN 
X-RAY PHOSPHOR SENSOR 
Introduction 
Advances in medical technology over the past 50 years have resulted in an 
increased number of patients who have implantable medical devices. The surface of 
implanted medical devices is a region of active chemistry due to bacterial infections, 
bone and tissue growth, and drug releasing stents.  For example, bacteria easily colonize 
implanted device surfaces and form biofilms with heterogeneous pH and oxygen 
environments that are highly resistant to antibiotics.
61-62
 Monitoring local changes in pH 
and other analytes would be valuable for detecting, studying, and monitoring in situ 
biofilm growth and chemistry. However, no conventional biomedical imaging techniques 
are able to perform high-resolution surface chemical imaging on surfaces. X-ray 
transmission and computed tomography (CT) have limited chemical sensitivity especially 
compared to optical techniques. Similarly, MRI and ultrasound provide high-resolution 
tissue imaging with limited chemical sensitivity.
63
 Positron emission tomography (PET) 
and single photon emission computed tomography (SPECT) image the location of 
radiolabeled molecules and have only ~1 mm resolution due to difficulties collimating 
the γ rays and due to the diffusion length of the positions. In additions, they do not have 
surface specificity. Optical microscopy is a powerful technique for chemical analysis in 
biological samples.  A wide variety of fluorescent and absorptive dyes are available for 
non-invasive, sensitive, specific, rapid, and high-resolution chemical imaging.  However, 
the utility of optical techniques is limited in tissues deeper than 1 mm as almost all light 
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is scattered (no ballistic photons).  It is difficult to reconstruct the original object from the 
blurred images except at low resolution.
58
 Confocal microscopy improves image 
resolution in thin tissues by raster scanning a focused illumination spot through the 
sample and rejecting out of focus light (not originating from the focal spot) via a pinhole 
aperture at the image plane. In deep tissue, however, the amount of unscattered photons 
decreases exponentially with depth, and the focal spot becomes very large once it is 
dominated by diffuse photons. In practice, conventional confocal microscopy works well 
through tissue samples up to ~200 μm deep and under best reported conditions with two-
photon NIR excitation up to about 1 mm deep.
64
 
Moronne used a related scanning X-ray technique to image optical emission from 
terbium-labeled actin in a single cell with ~50 nm resolution, far below the far-field 
optical diffraction limit.
49
 In addition, no pH or small analyte sensitivity was shown, and 
very large X-ray intensities were needed to excite light from a small number of dye 
molecules/pixel rather than a much larger area and volume from many scintillating 
particles in our work.  Chen and co-workers demonstrated that X-ray excited phosphor 
nanoparticles can transfer energy to fluorescent photodynamic dyes.
47-48, 65
 The suggested 
that similar X-ray phosphor/fluorescent particles could serve as oxygen dosiometers.
66
 
However, oxygen sensitivity and tissue imaging have not yet been shown. Recently, 
Pratx and co-workers developed X-ray luminescence computed tomography (XLCT) 
which detects the presence and location of X-ray phosphors in optically diffusive medium. 
Using less than 1~100 cGy of radiation dose, they achieved a spatial resolution of 1 mm 
through tissue-mimicking material based on the selective excitation of subpicomolar of 
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50 nm phosphor and optical detection of their luminescence.
54
 Pratx et al. also showed 
that XLCT could image the cross sectional distribution of microsize phosphor particles in 
1 cm of an agar tissue phantom.
41
  However, sensors for small chemical analyte which 
can be detected using indicator dyes have not yet been explored.  
    Herein, we demonstrate a versatile chemical sensing technique in tissue. The 
image is acquired point-by-point as the sample is scanned under the X-ray beam using a 
principle analogous to other scanning probe microscopies such as nearfield scanning 
optical microscopy, (NSOM). NSOM forms images by scanning a probe across a surface 
and measuring the amount of light transmitted or scattered at each location.
67
 The 
resolution of the image is largely defined by the size of the probe aperture (<50 nm for 
aperture NSOM), rather than the size of the spot on the photodetector (which must be at 
least as large as a diffraction limited spot). Chemical imaging NSOM is performed by 
coating modulate absorbance/fluorescence.
68
 Our technique uses a similar scanning light 
source to image local optical absorbance and chemical concentrations through tissue, 
however, rather than scanning a physical probe over the surface, our light source is a 
“virtual probe” formed by scanning a narrow X-ray beam across an X-ray phosphor film 
on the implant surface. The narrow X-ray beam serves as a local excitation light source 
for the phosphor film  and the  camera serves as a single pixel detector measuring total 
intensity of red and green light at each sample position. The phosphors are fabricated 
with a thin film containing indicator dyes to modulate the luminescence spectrum 
collected through the tissue.  Unlike conventional fluorescence microscopy, the X-ray 
beam is far less scattered by tissue than incident visible light so the “virtual probe size” 
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and image resolution is limited by the X-ray beam width.  We expect that the technique 
will be especially valuable for measuring concentrations of chemical analytes on the 
surface of films such as detecting local changes in pH due to biofilm colonization of 
implanted device surfaces. 
Results and discussion 
        In order to demonstrate the chemical sensitivity of our novel technique as a 
potential tool in diagnosis  of many diseases including cancer, infection, osteolysis, and 
antibiotic resistance,
69-70
 we developed a pH sensor by placing methyl-red dyed filter 
paper over a thin layer of X-ray phosphor powder (Gd2O2S:Tb, Phosphor Technology, 
Ltd. See Figure 2.1).   The phosphor and pH paper were irradiated with a narrow 
rectangular X-ray beam from an X-ray diffractometer (Ultima IV, Rigaku Inc.), and the 
visible luminescence was collected with an optical fiber-coupled spectrometer 
(BRC741E, BWTEK, Inc. USA). (See Figure 2.2) The spectrum was collected through a 
strip of pH paper at a specific pH, and then a motorized stage (MTS50 Thorlabs, Inc.) 
moved the sample to another pH paper strip at a different pH. The phosphor spectrum 
displayed sharp peaks which were modulated by the pH-dependent absorbance of the 
filter paper.  
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Figure 2.1 An X-ray excited pH sensor, formed by measuring spectra X-ray excited 
luminescence through methyl red-dyed paper.  (A) Schematic, (B) Spectra of Gd2O2S:Tb 
through methyl red paper at different pHs, (C) Calibration curve: peak ratio as a function 
of pH. Error bars represent the standard deviation of 5 replicable trials. Reprinted with 
permission from ref. 112. Copyright 2011 American Chemical Society. 
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Figure 2.2 Photograph of experimental setup for measuring pH by detecting 
luminescence spectrum through methyl red dyed filter paper. Reprinted with permission 
from ref. 112. Copyright 2011 American Chemical Society. 
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Figure 2.3 XRD patterns of the phosphor powders. (a) Gd2O2S:Tb (green) phosphor, (b) 
Gd2O2S:Eu (red) phosphor. Reprinted with permission from ref. 112. Copyright 2011 
American Chemical Society. 
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       Rare earth oxysulfide phosphors have been widely used for X-ray detectors due to 
their robustness and large quantum efficiency for X-ray to visible light conversion 
(~60,000 visible photons/MeV).
16, 71
 Previous studies also showed rare earth ions such as 
Gd and Eu are not highly toxic: LD50 for intravenous injection is 10-100mg/kg.
72
 For 
example, gadolinium MRI contrast agents are used in 20 million scans per year with an 
average dose of 1.2 g/patient.
73
 The relatively low toxicity, chemical stability, and 
resistance to photobeaching
 
of rare earth oxysulfide phosphors make them ideal labels in 
physiology conditions.
74-75
 For our application, the multiple narrow and intense spectral 
luminescence peaks are advantageous because they are readily distinguished from 
phosphors doped with other rare earth elements and secondary emission from fluorescent 
dyes. As shown in Figure 2.1B, the intensity of the 538 nm luminescence changes with 
pH because of changes in the dye absorbance spectrum. The intensity of peak at 613 nm, 
however, was relatively constant and provides a reference. A calibration curve (Figure 
2.1C) shows a dynamic range of pH 6-9 (note the pKa of the dye shifted upon adsorption 
to the paper). The noise level between pH 7 and 8 was calculated to be 0.05 pH unit 
(based on standard deviation and slope).  
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Figure 2.4 Demonstration of imaging with X-ray limited resolution. Green X-ray 
phosphors (Gd2O2S: Tb) and red phosphors (Gd2O2S: Eu) were deposited in a film with a 
sharp interface between the red and green sections. The film was irradiated by a 2.0 mm 
X-ray beam and a photograph was acquired at a series of sample positions (0.5 mm per 
step). (A) Photo of phosphor film with X-ray beam excitation and room light. (B), (C), 
(D) photo of luminescence (with room light blocked) as the sample was moved across the 
red/green (Tb/Eu) phosphor interface. The positions of each figure were 5.5 mm, 6.5 mm, 
7.5 mm.  (E) Same image as (A) but with the film covered by a filter paper at a distance 
of 10 mm. (F), (G), (H) corresponding to (B), (C), (D), respectively, but with the film 
covered with a filter paper. The Luminescent image is blurred by the scattering in the 
filter paper. Reprinted with permission from ref. 112. Copyright 2011 American 
Chemical Society. 
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        Poor spatial resolution due to scattering is the most significant limitation of 
conventional optical microscopy in thick tissue. To demonstrate the effect of scattering 
upon resolution, we fabricated a two-component film with a region of Gd2O2S:Tb (green 
luminescence), a second region of  Gd2O2S:Eu (red luminescence), and a sharp interface 
between the two regions. A 2 mm wide X-ray beam was used to excite optical 
luminescence at different regions of the film before and after adding a piece of filter 
paper above the sample to introduce scattering (See Figure 2.4). When the interface was 
illuminated, the green and red phosphor films regions can be easily resolved before the 
filter paper is added. After the paper is placed 1 cm above the sample, however, the 
luminescence spot blurs and the color looks homogeneous. This color depends upon 
which region is irradiated, thus scanning X-ray excited optical luminescence image is 
convolved with the X-ray beam profile, thus the spatial resolution depends upon the beam 
width. To image the phosphor interface at higher resolution through a scattering medium 
we reduced the X-ray slit width to produce a narrower X-ray beam (260 μm width). For a 
more realistic imaging scenario, we also replaced the filter paper with chicken breast 
tissue.(Figure 2.5). The luminescence was imaged with a Nikon D90 digital camera as the 
sample position was scanned relative to a fixed X-ray beam (Figure 2.5 C-F). The 
phosphor film was then sandwiched between two 10 mm thick sections of chicken breast 
and the experiment was repeated (Figure 2.5 B and G-J). Although the optical image 
blurred to 8.5 mm after the phosphor film was inserted into the chicken breast, the color 
indicated which region was under excitation. In our analysis, we treat the camera as a 
single pixel detector and measure the total red, green, and blue pixel intensity in each 
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picture using MATLAB scripts.  The 90%/10% knife-edge resolution was 0.16 mm 
without tissue, and 0.17 mm with tissue; the full knife-edge resolution including the most 
tails was approximately 0.26 mm without tissue and 0.30 mm with tissue (Figure 2.6). 
The small resolution increase in the tissue was likely due to imperfect sample alignment 
and scattering of the incident X-rays in the tissue.  
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Figure 2.5 Example of imaging XEOL with X-ray limited resolution. Green X-ray 
phosphors (Gd2O2S:Tb) and red phosphors (Gd2O2S:Eu) were deposited in a film with a 
sharp interface between the red and green sections.  The film was irradiated by a narrow 
rectangular X-ray beam and a photograph was acquired at a series of sample positions (20 
µm steps). (A) Setup schematic. (B) Setup photograph. (C) Photo of phosphor film with 
X-ray beam excitation and room light. (D), (E), (F) Photo of luminescence (with room 
light blocked) as the sample was moved across the red/green (Tb/Eu) phosphor interface. 
(G) Same image as (C) but with the film inserted between two 10 mm thick sections of 
chicken breast. (H), (I), (J) corresponding to (D), (E), (F), respectively, but with the film 
inserted into chicken breast. The luminescent image is blurred by the scattering in the 
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tissue from 0.26 mm to ~8.5 mm. The color ratio is shown as a function of position in 
Figure 2.6.  The positions of D, E, F and H, I, J in Figure 2.5 were 0.12 mm, 0.22 mm, 
0.42 mm, respectively. Reprinted with permission from ref. 112. Copyright 2011 
American Chemical Society. 
 
Figure 2.6 Ratio of red to green light intensity scanned at different positions (20 µm step 
size) with/without 10 mm of tissue. It gives evidence of optical contrast at 0.30 mm 
resolution through 10 mm chicken tissue. Reprinted with permission from ref. 112. 
Copyright 2011 American Chemical Society. 
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          The technique has three advantages compared to conventional X-ray absorption 
images.  First, indicator dyes provide chemical sensitivity. Second, phosphor 
luminescence is a positive contrast mechanism with essentially no background, while 
conventional X-ray transmission imaging detects small changes in the relatively large 
background of transmitted X-rays, although contrast is enhanced using barium, gold 
nanoparticles and other contrast agents.
76 
The positive contrast allows relatively non-
invasive X-ray doses to be used. For phosphor films, doses are typically equal to or less 
than that used in conventional X-ray imaging, except with blue light or deep tissue where 
tissue absorbance can reduce total signal intensity. Third, multiple phosphors may be 
used with distinguishable spectra for multiplexed imaging. It should be noted that 
conventional X-ray images can be co-registered simultaneously with luminescence if X-
ray detectors are used to capture the transmitted X-rays while the optical detectors 
measure luminescence. 
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         A visible/near-infrared point light source in an infinite tissue slab is attenuated by 
a factor of 3 to 300 per cm of tissue depending on the type of tissue and wavelength 
used.
77
 Spectral distortion remains a potential problem for our technique, although the use 
of lanthanide phosphors with long lifetimes and narrow peaks can greatly mitigate the 
problem. Spectral distortion is caused by effective attenuation in tissue which is 
wavelength dependent according to the photon diffusion model:  
                                                                ))
                     (2) 
          Where μeff is the effective attenuation coefficient, μa is the absorption coefficient, 
and μs’ is the reduced scattering coefficient.
78-79
 For example, although figure shows that 
the spatial resolution was hardly affected by the 10 mm thick chicken breast, it is also 
evident that the red/green ratio increased, especially for the Gd2O2S:Tb phosphor because 
the 538 nm light is more rapidly attenuated than the 613 nm light. The methyl red 
absorption causes a similar effect, thus the chicken breast tissue can cause interference if 
not adjusted for. The tissue absorbance disproportionately affects the color ratio detected 
by the digital camera because the camera filters are not tuned to the luminescence peaks. 
However, the shift is considerably smaller between two nearby spectral peaks (e.g. 613 
nm and 620 nm in the Gd2O2S:Tb and Gd2O2S:Eu phosphors, see Figure 2.7).  In 
addition, there are several ways to address the spectral distortion such as a function of 
time. Phosphorescence lifetime is alternative approaches which are not affected much by 
scattering. Photoacoustic imaging is the only other technique that can provide high-
resolution visible imaging deep in tissue. Both X-ray phosphor imaging and 
 29 
photoaccoustic imaging avoid the problems of visible light scattering by converting 
between visible light and another energy source.  
 
Figure 2.7 Luminescent spectra of Gd2O2S:Tb and Gd2O2S:Eu phosphors. Reprinted with 
permission from ref. 112. Copyright  2011 American Chemical Society. 
       Photoaccoustic microscopy measures acoustic waves generated by photothermal 
expansion of tissue that absorbs a short pulse of intense light. The acoustic waves 
generated are far less scattered than the optical waves and the image resolution is limited 
by the acoustic transducer (45 µm lateral resolution and 3 mm imaging depth with a 50 
MHz transducer) rather than the optical diffraction.
80
 The main limitations are that (a) 
tissue scattering and absorption cause spectral distortions, and no lifetime discrimination 
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techniques are available, (b) bone and metal can cause spatial distortions, (c) 
photoacoustic microscopy requires a wavelength tunable high power pulsed laser, and (d) 
samples must be immersed in an acoustic bath.   
Conclusion 
        In summary, we developed a novel technique for in situ chemical imaging in 
tissue. It combines chemical sensitivity from indicator dyes, demonstrated by the pH 
sensor, with high spatial resolution, demonstrated by detecting a two-color X-ray 
phosphor object with 0.30 mm resolution through 10 mm of chicken breast.  The 
technique is sensitive because it is essentially background-free.  The X-ray phosphors 
with different emission spectra make them versatile sensing agents for colorimetric 
detection. Future work involves using chemical indicator dyes for oxygen and other 
analytes, developing lifetime-based chemical sensors which will not be affected by tissue 
attenuation, using narrower X-ray beams and more sensitive detection optics for two 
dimensional chemical imaging and tomography, and developing a portable imaging 
system.  Two dimensional chemical imaging will be especially useful for measuring 
chemical changes on a surface, such as in situ detection of acidosis, hypoxia, and 
hydroxyapatite degradation on implanted devices with bacterial colonies.
62, 81
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Experimental Section 
Materials  
        Methyl Red (C15H15N3O2) and filter paper (medium porosity) were purchased 
from Fisher Scientific Co. (Fair Lawn, NJ, USA). pH buffers solution was purchased 
from BDM Chemicals Ltd (Poole, Dorset, UK). Terbium-doped gadolinium oxysulfide 
phosphor powder (Gd2O2S:Tb) and Europium doped Gadolinium oxysulfide (Gd2O2S:Eu) 
were purchased from Phosphor Technology Ltd. (Stevenage, UK).  Both Gd2O2S samples 
contained microparticles that ranged in size from 2-15 µm with a nominal diameter of 8 
µm.  Carboxymethyl cellulose sodium was purchased from TCI (Tokyo, Japan). Cover 
glass was purchased from Electron Microscopy Sciences (Fort Washington, PA, USA). 
Deionized (DI) water and ethanol were purchased from EMD Chemicals Inc. (Gibbstown, 
NJ, USA). Chicken breast was purchased from Coleman Natural Foods, Inc. (Golden, CO, 
USA). All chemicals were used as received without further purification.  
Preparation of phosphor film: 1.0 g Gd2O2S:Tb phosphor powder was mixed with 2 
mL carboxymethyl cellulose sodium aqueous solution (0.5% w/v) and the entire solution 
was applied to a cover glass (24×60 mm) and allowed to dry overnight. The film of 
Gd2O2S:Tb and Gd2O2S:Eu phosphor coated on the same glass slide (25×75 mm) was 
prepared in a similar way. 0.5 g Gd2O2S:Tb phosphor and 0.5 g Gd2O2S:Eu phosphor 
were each drop-coated onto a separate cover glass (24×60 mm). These two phosphor-
coated cover glasses were brought together and stuck to a glass microscope slide (25×75 
mm) using double-sided tape. 
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Preparation of methyl red dyed filter paper and pH measurement: A 12×100 mm 
strip was prepared from filter paper of medium porosity and this strip was immersed in 
600 µL ethanolic solution of methyl red (0.05% w/v) over night and dried thoroughly. 
The ethanolic solution of methyl red (0.05% w/v) was prepared by adding 0.0010 g 
methyl red powder into 2.00 ml ethanol. The 12×100 mm methyl red dyed strip then was 
cut into a series of 12×8 mm pH-strips. After that, these pH-strips were placed onto a No. 
0 coverslip covering the phosphor film as shown in Figure 2.2. A series of calibrated pH 
buffer solution (pH 2.00-13.00) were then pipette onto each pH strip (10 µL). The stage 
was moved so that each pH strip was irradiated and a series of five spectra were recorded 
from different areas of the strip to determine the average and standard deviation of the 
peak intensity ratio, as shown in Figure 2.1.      
Instrumentation 
            To determine the phase of the samples, X-ray powder diffraction was performed 
at 40 kV and 40 mA using a Rigaku Ultima IV X-ray diffractometer with CuKα radiation 
at a scanning rate of 0.5º/min from 5º to 70º. The XRD patterns (Figure 2.3) were almost 
identical.  They displayed narrow peaks indicative of particles with average crystal 
domains > 90 nm in diameter.  
            For X-ray phosphor luminescence, the X-ray diffractometer was operated at 120º 
with tube voltage of 40 kV and tube current of 50 mA. Luminescent spectra were 
captured at room temperature with a FPC-400-0.22-1.5-UV fiber coupled photodiode 
array spectrometer (BRC741E-02 BWTEK Inc, Newark, DE, USA).The stepper motor 
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stage (MTS 50, Thorlabs, Inc. Newton, NJ, USA) was controlled by a program written in 
Labview (National Instruments, Austin, TX, USA).   
            The luminescent images in Figure 2.4 were taken with a Nikon D90 digital 
camera with a 67 mm diameter lens at 50 mm FL and a macro lens adaptor.  All the 
parameters of the camera were controlled by the software of Camera Control Pro2 (Nikon 
Instruments Inc., Melville, NY, USA). The images without chicken breast (Figure 2.4 C-
G) were taken at ISO=200, shutter speed 1/4 s, f/5.6. The images with the phosphor 
between two 10 mm thick sections of chicken breast (H-J) were taken at ISO=2000, 
shutter speed 30 s, and aperture f/4.0. The increased exposure time, ISO and aperture 
were necessary because the luminescence was dispersed over a wider area (~8.5 mm 
instead of 0.26 mm), and the light and X-ray beam were attenuated by passing through 
the tissue. A more sensitive detector (e.g. a photomultiplier tube or avalanche photodiode) 
would require far shorter exposure times.  All images were analyzed by Matlab R2008b. 
            In order to determine the X-ray beam width in Figure 2.4, we measured the ratio 
of red/green intensity at the interface between the Gd2O2S:Tb and Gd2O2S:Eu phosphor 
films.  In addition to this intensity ratio we also measured absolute green intensity of a 
phosphor film edge, which provided a similar beam width 0.26 mm as shown in Figure 
2.6. 
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                                                           CHAPTTER THREE 
III. OPTICAL IMAGING IN TISSUE WITH X-RAY EXCITED LUMINESCENT 
SENSORS  
Introduction 
           Non-invasive biomedical imaging techniques are important for diagnosing 
diseases studying disease processes.  Bright-field and fluorescence microscopy are 
excellent techniques for chemical imaging in cells and thin tissue sections (<~200 µm) 
because a wide range of fluorescent indicator dyes and nanoparticles are available that 
provide high chemical sensitivity and selectivity. However, optical microscopy is of 
limited utility in tissues deeper than 1 mm because almost all light is scattered causing 
poor resolution.
82-83
  For tissue imaging other techniques are used such as X-ray 
transmission and computed tomography (CT), ultrasound, and magnetic resonance 
imaging (MRI).  These techniques provide high spatial resolution, but have limited 
chemical sensitivity especially compared to optical techniques.
84
  Positron emission 
tomography (PET),
85
 single photo positron emission computed tomography (SPECT),
86
 
and Cerenkov radiation optical imaging
87
 are used to measure the in vivo distribution of 
injected radioactive analytes. However, detection is limited in that the analyte must be 
radiolabelled, the resolution is typically in millimeters, and there is only a relatively short 
observation half-life (typically hours). Herein, we report a novel high-spatial resolution 
imaging technique to measure optical absorption and detect chemical and physical 
changes through thick tissue. The technique uses a narrow X-ray source to excite 
luminescence from X-ray phosphors at a resolution limited by the X-ray beam-width. The 
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phosphors serve as light sources with spectra and intensity that depend on local 
absorption. Here we detect changes in luminescent intensity and spectrum due to 
deposition of silver and gold nanoparticles onto the phosphors. We demonstrate imaging 
of silver and gold patterns through 10 mm pork, and describe the mechanism of 
luminescent attenuation.  
              Rare earth oxysulfide phosphors we used in this study have been widely used for 
X-ray detectors due to their robustness and large quantum efficiency for X-ray to visible 
light conversion.
16, 18, 71, 88
  Previous studies also showed rare earth ions such as Gd
3+
 and 
Eu
3+
 are not highly toxic: LD50 for intravenous injection is 10-100mg/kg.
72
 For example, 
chelated gadolinium MRI contrast agents are used in 20 million scans per year with an 
average dose of 1.2 g/patient.
73
 The relatively low toxicity, chemical stability, and 
resistance to photobeaching of rare earth oxysulfide phosphors make them ideal labels in 
physiology conditions.
74-75
  They are used in X-ray excited optical luminescence (XEOL) 
to map luminescent centers in semiconductor and rare-earth doped materials.
89-90
 The 
principle can also be applied to detection of scintillation in cell labeling studies, for 
example, Morrone used a form of scanning X-ray excited optical luminescence (XEOL) 
to image optical emission of terbium labeled actin in a single cell and obtained a ~50 nm 
resolution.
49
 However, other optical techniques are available for near-field imaging in the 
absence of scattering,
91-92
 and they did not apply their technique to the challenge of tissue 
imaging where light scattering causes far more severe blurring (typically a ~10 mm point 
spread for imaging through 10 mm of tissue). Adam and coworkers also proposed using 
quantum dots for multiplexed cell labeling XEOL experiments using a table-top soft X-
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ray source.
50
 Chen et al demonstrated energy transfer between X-ray excited phosphor 
nanoparticles which caused X-ray excited photodynamic, therapy,
48, 65-66
 but chemical 
sensitivity and tissue imaging have not yet been shown. Recently, Pratx and co-workers 
developed X-ray luminescence computed tomography (XLCT) which detects the 
presence and location of X-ray phosphors in optically diffusive medium. Using 1-100 
cGy of radiation dose, they achieved a spatial resolution of 1 mm through tissue-
mimicking material based on the selective excitation of subpicomolar of 50 nm phosphor 
and optical detection of their luminescence.
54
 Pratx et al. recently showed that XLCT 
could image the cross sectional distribution of microsize phosphor particles in 1 cm of an 
agar tissue phantom.
41
 However, sensors for small chemical analyte in thick tissue have 
not yet been explored. We demonstrate below that scanning XEOL can be used for high-
resolution imaging of local optical absorption through tissue.   
Results and discussion 
Imaging silver coating on X-ray phosphors in 1 cm tissue 
           High-resolution imaging of small features through tissue can be challenging.  
Conventional X-ray imaging detects attenuation of transmitted X-ray photons, and 
contrast requires a relatively large change in sample thickness or density.  However, 
XEOL is a positive contrast method which can detect lower concentrations of particles.  
In addition, it is able to detect local absorption from indicator dyes and inorganic 
materials, which enables high contrast and chemically specific imaging. For example, 
gold has an X-ray absorption cross section of only a factor of ~1000×  more than tissue, 
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while the visible and NIR attenuation constant for a gold nanoparticle can be 10
8
 times 
larger than tissue allowing detection of nanometer thick gold films through a centimetre 
of tissue.  
 
Figure 3.1 (A) Schematic of the scanning X-ray excited optical luminescence (XEOLs) 
absorption imaging technique. (B) Spectra of europium doped gadolinium oxysulfide 
(Gd2O2S:Eu) film either uncoated or coated with 5 nm of vapour deposited silver. As a 
control for whether silver contact was needed to attenuate XEOL, a glass slide coated 
with 5nm of silver was also placed beneath the phosphor. Reproduced from Ref. 123 with 
permission from the Royal Society of Chemistry. 
 
             Gold and silver nanoparticles are especially interesting materials for 
spectrochemical sensors because they support a localized surface Plasmon resonance 
(LSPR) mode, which provides intense sized- and shape-dependent optical absorption and 
scattering spectra.
93
 They are used in a wide variety of chemical sensors based upon 
refractive index changes as well as nanoparticle aggregation and disaggregation.
94-95
 
Silver nanomaterials are also important antimicrobial agents and have been proposed as a 
method to prevent and reduce implant associated infection.
95-96
 Methods to study the in 
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situ silver dissolution rate and amount of silver coating remaining would thus be valuable 
for evaluating antimicrobial efficacy and silver toxicity.   
            To demonstrate that a thin silver coating can be detected and imaged using 
scanning tissue XEOL, we formed a monolayer of 8 µm Gd2O2S:Eu phosphor on tape, 
and vapour-deposited a 5 nm thick silver film onto one side of the film. A physical mask 
was employed so that one region was silver-coated and another left uncoated with a sharp 
transition between the two regions.  The silver coated film was irradiated with X-rays, 
and the luminescence intensity was measured as shown in Figure 3.1.  The intensity of 
the silver-coated region was attenuated by 51% (at 617 nm) compared to the uncoated 
region.  Direct coating of the silver onto the phosphors was required: a control prepared 
by placing a 5 nm silver-coated cover glass beneath the same slide of uncoated sample 
resulted in an increase of intensity (5%) rather than reduction because of increased 
reflection (see Figure 3.1 B). 
           The multiple narrow and intense spectral luminescence peaks of Gd2O2S:Eu are 
advantageous because they are easily distinguished from secondary emission of 
fluorescence from tissue. The strong red and near infrared luminescence peaks are only 
weakly absorbed by tissue, although scattering greatly reduces resolution. 
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Figure 3.2 (A) Schematic of the scanning X-ray excited optical luminescence (XEOLs) 
absorption imaging technique in tissue. (B), (C) Intensity of red light scanned at different 
positions with/without 10 mm of tissue. The full-width resolution is 1.7 mm through the 
pork tissue (half-width is 0.85 mm). (D) Setup photograph of X-ray phosphor film under 
10 mm pork. (E) Photograph of XEOL for the X-ray beam on a region of bare phosphor. 
(F) Photograph of XEOL for a region of silver-coated phosphor.  (G), (H) Same image as 
(E), (F) but with the film under 10 mm thick section of pork, and with a larger exposure 
time (30 s).  Reproduced from Ref. 123 with permission from the Royal Society of 
Chemistry. 
 
           To measure the spatial resolution of the scanning XEOL, a rectangular X-ray beam 
(1.7 mm × 10 mm) irradiated the silver-coated phosphor sample through 1 cm of pork 
tissue (Figure 3.2 A, D).  The luminescent intensity was imaged with a Nikon D90 digital 
camera as the sample position was scanned relative to a fixed X-ray beam. Although each 
optical image showed a blurred 10 mm luminescence region due to scattering, the 
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intensity and spectrum was modulated by local optical absorption.  The total red, green, 
and blue pixel intensity in each picture was analyzed in Matlab. The total intensity 
collected as a function of position shows a clear knife-edge profile with a full-width of 
just 1.7 mm through 10 mm of tissue (Figure 3.2C), limited by the X-ray beam width. 
The slight broadening from 1.6 mm without the tissue is likely due to misalignment of the 
phosphor film after placed under 1 cm pork, or a halo effect from scattering of soft X-
rays.   
Attenuation Mechanism 
           Having demonstrated high spatial-resolution imaging through tissue, we decided 
to investigate the mechanism by which silver attenuated XEOL.  Three potential 
mechanisms were initially considered. (a) Irreversible damage to the phosphor during 
vapour deposition. This mechanism was ruled out after we showed that the intensity 
recovered when the silver was dissolved in H2O2. (b) Energy transfer and dynamic 
quenching of the Eu excited state by the silver nanoparticles.  Silver and gold are known 
to be efficient fluorescence quenchers
97-98
 and research by Chen and co-workers 
demonstrated that nanophosphors are able to transfer their energy to generally less 
efficient fluorescent dye.
99-100
 However, the phosphor particles had an average diameter 
of 8 µm, and Forster energy transfer generally occurs over distances <10 nm and would 
therefore only be efficient near the surface of the particle unless there is very long 
lifetime and efficient energy diffusion to the surface. The hallmark of dynamic energy 
transfer is a decrease in the excited state lifetime, which was measured below. (c) Local 
absorption of light by the silver nanoparticles, i.e. the “inner filter effect.” Since the 
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phosphor particles are significantly larger than the wavelength of light, we expected 
geometric optics to largely apply. However, no direct absorption was possible because 
the silver was deposited beneath the phosphors and the camera was imaging from above 
(see Figure 3.1).   
             Based on the experiments outlined in Figure 3.1A, the likely mechanism is 
indirect absorption due to attenuated total internal reflection. We also note that a 5 nm 
silver film deposited on the top rather than bottom side of the phosphors reduced the 
luminescence intensity by a total of 61% (at 617 nm) when viewed from above. (see 
Figure 3.3). The intensity is reduced because the silver lies between the phosphor and the 
camera and acts as a filter. 
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Figure 3.3. (A) Different mode of luminescent attenuation compared with reference 
region, (B) Luminescence spectra of different region of phosphor film. Reproduced from 
Ref. 123 with permission from the Royal Society of Chemistry. 
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Luminescence Lifetime 
To determine if the silver caused dynamic quenching of the X-ray luminescence, we 
measured the XEOL lifetime. An optical chopper was placed in front of the X-ray beam 
and rotated at 250 Hz.   A small amount (~3%) of X-ray energy passes through the 1 mm 
thick Al chopper wheel even in the blocked state; however, a clear signal modulation is 
evident (see Figure 3.4).  The luminescence lifetime(s) was determined from the shape of 
the curve. After a short transition period while the chopper shifts from not blocking the 
X-ray beam to fully blocking the beam, the intensity is expected to decay exponentially 
as follows: 
0( )
t
I t I e 


 
where I(t) is the intensity at time, t, I0 is the intensity at time t=0, and τ is the 
luminescence lifetime of the X-ray phosphor. A plot of ln(I) vs. t shows a linear curve 
indicating a single lifetime over the observed timescale (Figure 3.4B, C). The lifetime of 
phosphor luminescence from silver coated and uncoated samples is 0.387 ms and 0.390 
ms, respectively. The lifetimes are similar to the nominal value quoted for the Gd2O2S:Eu 
phosphor of no more than 0.45 ms.
101
 The unchanged lifetime between coated and 
uncoated samples indicate that dynamic quenching was not responsible for attenuated 
XEOL intensity, and absorption is the most likely alternative.   
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Figure 3.4 (A) Luminescence responses resulting from X-ray pulse at 250 Hz measured 
with a photomultiplier tube (B). (C) Plot of the log of the intensity vs. time after the 
chopper blocked the X-ray beam.  Digitization noise is evident at low intensities.  
Lifetimes for coated and uncoated samples are 0.387 ms, and 0.390 ms, respectively. 
Reproduced from Ref. 123 with permission from the Royal Society of Chemistry. 
Effect of silver film thickness on luminescent absorption  
         To determine if absorption was responsible for the reduced XEOL intensity, we 
measured the XEOL intensity at various wavelengths as a function of silver film 
thickness.  We reasoned that if absorption were responsible, the signal would be smaller 
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at wavelengths which are more strongly absorbed by silver nanoparticcles. The LSPR 
absorption spectrum depends strongly on nanoparticle shape. Silver island film 
nanoparticles are formed during vapour deposition, and as more silver is deposited the 
particles become flatter until a continuous film is formed. Figure 3.5 shows SEM images 
of progressively thicker silver film deposition.  The particles change in shape from small 
and approximately spherical to larger flatter particle shapes and eventually continuous 
films with some surface roughness.  For particles deposited upon a flat glass surface, this 
change in shape leads to a larger transverse LSPR resonance and a red-shift in extinction 
spectrum as shown in Figure 3.6A. When the silver is deposited upon the angled and 
faceted surfaces of the phosphor microparticles the extinction spectrum (Figure 3.6B) is 
blue-shifted compared with the spectrum on flat glass due to changes in nanoparticle 
orientation and shape.  
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Figure 3.5 SEM images of (A) phosphor particles (B)-(F) Close up view of the phosphor 
surface coated with different thicknesses of silver:  (B) 0 nm silver, (C) 3 nm, (D) 5 nm, 
(E) 10 nm, (f) 20 nm. Reproduced from Ref. 123 with permission from the Royal Society 
of Chemistry. 
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Figure 3.6 (A) Extinction spectra of silver film on cover glass (cover glass was used as 
the reference). All spectra are normalized to Amax=1. The real Amax for 1, 3, 5, 10, 20, 30, 
40, 50, 60 nm are 0.02, 0.17, 0.31, 0.59, 0.84, 1.25, 1.60, 1.95, and 2.23, respectively. (B) 
Extinction spectra of silver film on phosphor particles (phosphor film coated cover glass 
was used as the reference). All spectra are normalized to Amax=1. The real Amax for 1, 3, 
5, 10, 20, 30, 40, 50, 60 nm are 0.02, 0.09, 0.14, 0.51, 0.55, 0.69, 0.83, 0.87, and 0.90, 
respectively. Inset shows a photograph of the silver coated phosphor film. Reproduced 
from Ref. 123 with permission from the Royal Society of Chemistry. 
          The XEOL spectrum depended on the silver deposition thickness (see Figure 
3.7A).  The variation of relative luminescence lost for film from 1 nm to 10 nm can be 
explained by the size and shape-dependent absorption properties of the nanparticles in the 
silver island film. (See Figure 3.6). In general, the luminescent attenuation order for each 
peak is 588 nm> 608 nm> 617 nm> 697 nm which is consistent with the extinction 
spectra of silver film on phosphor particles (Figure 3.6B). For films thicker than 10 nm 
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(more than the optical penetration depth of silver), the silver largely behaves as a lossy 
mirror, and the attenuation effect saturates.   
 
Figure 3.7 (A) Luminescent spectra of Gd2O2S:Eu phosphor coated with different 
thickness of silver film. (B) Relative luminescence loss ((Iuncoated-Icoated)/Iuncoated×100%) 
varies with different thickness of silver. Reproduced from Ref. 123 with permission from 
the Royal Society of Chemistry. 
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Figure 3.8 (A) Luminescent intensity at 617 nm in air and oil. (B) Relative luminescent 
intensity loss ((Iuncoated-Icoated)/Iuncoated×100%) in air and oil. Reproduced from Ref. 123 
with permission from the Royal Society of Chemistry. 
       The above experiments indicated that absorption was the most likely explanation 
for the silver attenuation because the attenuation showed a spectra dependence that was 
consistent with the silver nanoparticle extinction spectrum.  However, since the silver 
coating was beneath the phosphors, and the camera and spectrometer detected light 
emitted through the top of the particles, the silver must absorb light that would otherwise 
be reflected from the bottom of the particles (e.g. due to refractive index mismatches). 
The refractive index of Gd2O2S:Eu is between 2.1 and 2.3 RIU.
102
 Assuming an 
intermediate refractive index of 2.2, the phosphor/air interface has a critical angle of 27º 
which corresponds to reflection from a solid angle of 1.82π2, or 91% of an incident 
angles. In addition, 14% of normally incident light reflected at the Gd2O2S/air interface. 
For comparison, the critical angle for the phosphor/double-sided sticky tape interface is 
42º, assuming a refractive index of 1.5 for the tape, this corresponds to reflection from a 
solid angle of 1.54π2 or 77% of incident angles; the normal reflection coefficient is 3.6%.   
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      Therefore, most of the light is reflected once or more and most of light is emitted 
through the top of phosphor/tape interface.  This hypothesis explains why a silver coating 
below affects the light above. It also explains why placing a mirror below the phosphors 
increases the luminescence, but by less than a factor of 2 (see Figure 3.1B).  To further 
test this hypothesis, we incubated the phosphor film in microscope immersion oil with a 
refractive index of 1.518 RIU (see Figure 3.8). The overall intensity of light collected 
through the top of the film decreased, consistent with a decrease in reflection from the 
bottom surface (Figure 3.8A).  In addition, the relative effect of attenuation from silver 
absorption was less significant after adding oil which is consistent with a reduced amount 
of internal reflection (Figure 3.8B). These results support the internal reflection 
hypothesis. Internal reflection increases the effective absorption path length and enhances 
local absorption from nanoparticles and dyes on the surface which is adventurous for 
measuring small changes in absorbance.  Furthermore, the particles can be designed to 
detect changes in local refractive index, a feature which can be employed to observe 
label-free protein binding and polymer degradation.  
Dissolution of silver nano-film in H2O2 
          Hydrogen peroxide plays a significant role in cell biology. It is a messenger 
molecule for a wide variety of processes including cell development and programmed 
cell death.
103-104
 It is produced by macrophages to destroy pathogens and also serves as an 
inflammatory marker. H2O2 is also produced in many aerobic processes and enzymatic 
reactions. These reactions are often used in electrochemical analysis, for example glucose 
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is routinely detected by electrochemically measuring the amount of H2O2 produced in the 
presence of glucose oxidase
105
 and peroxidise enzymes. 
           Silver is an important antimicrobrial agent which is found in a wide variety of 
cosmetics and textiles, and has been proposed as an antimicrobial agent for implanted 
medical devices.
106-107
 Recently there have been several studies of the reaction rate of Ag 
with H2O2 in different pH and temperature conditions. The overall reaction is shown 
below.
108-109
   The reaction is sensitive to concentrations of salts and enzyme, for example 
Liu et al. showed an increase in reaction rate with decrease in pH, and proposed a 
hydroxyl radical intermediate (OH•),108 while Ho et al. found an increase in reaction rate 
with increasing pH (due to reaction of HO2
-
) and no hydroxyl intermediate.
109
   A 
technique capable of measuring in situ silver dissolution would therefore be useful.   
2Ag (s) + H2O2 → 2Ag
+
(aq) + 2OH
-
 (see ref.27, 28) 
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Figure 3.9 Luminescent intensity at 617 nm as a function of time during silver dissolution 
in 1 mM H2O2. Reproduced from Ref. 123 with permission from the Royal Society of 
Chemistry. 
          To study the dissolution of a silver island film in H2O2, 5 nm of silver was vapour 
deposited upon a Gd2O2S:Eu phosphor film, and the luminescent spectra were recorded 
in time during dissolution in a 1 mM H2O2 aqueous solution. The dissolution of the silver 
was indicated by the increase in luminescent intensity. As shown in Figure 3.9, after the 
silver film dissolved in H2O2, the luminescent intensity recovered to normal intensity 
within experimental error from sample to sample variation.  Although 1 mM H2O2 
concentration is a very high level for physiological conditions,
110-111
 the dissolution was 
relatively rapid (30 min), compared to a few weeks in physiological conditions.  For 
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example, assuming that rate is proportional to concentration,
108-109
 30 minutes at 1 mM 
corresponds to a 7 µM concentration dissolving in 3 days or 700 nM over one month.  In 
addition, the physiological rate may be different due to changes in pH, increased 
temperature (37 ºC instead of 23 ºC), extracellular components including chloride ions 
and metal binding enzymes, adsorption of protective proteins, and mechanical abrasion. 
The ability to tune the silver thickness and location presents a promising method to study 
dissolution kinetics in vivo. 
Imaging silver dissolution through tissue 
        To detect low concentrations of H2O2 (1 mM) in thick tissue with high spatial 
resolution, we use a narrow X-ray beam to excite the phosphor film. We selected a 5 nm 
thick silver film on Gd2O2S:Eu since the luminescent reduction is enough to distinguish 
(Figure 3.8A) and the small particle size reduces the time required to dissolve the silver 
(Figure 3.9). The silver coated phosphor film was incubated in 1 mM H2O2 solution (100 
μl of 30% (w/w %) H2O2 solution was added in 1000 ml DI water (pH 5.5)) at room 
temperature for 3h. We also deposited a 5 nm thick strip of gold as a chemically inert 
control. Figure 3.10 shows that the 5 nm gold film reduces the intensity more than the 5 
nm silver film. This intensity difference and the stability of gold in physiological 
conditions make the gold film a good reference and fiduciary marker.  
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Figure 3.10 Luminescent spectra of phosphor film with 5 nm of silver and 5 nm of gold 
film. Reproduced from Ref. 123 with permission from the Royal Society of Chemistry. 
 
 
         In order to image local changes in silver absorbance, we masked some regions of a 
silver film with double sided sticky tape prior to exposure to 1 mM H2O2. Figure 3.11A is 
a photograph of a phosphor film coated by a strip of silver 5 nm thick and 7.4 mm wide 
as well as a strip of vapour-deposited gold, 5 nm thick and 2.3 mm wide. Two regions of 
the silver film were masked with thin strips of tape so that only a strip in the center was 
unprotected. The sample was plasma etched for 5 min in air plasma to make all regions 
hydrophilic.  The sample was then incubated in H2O2 for 3 hr to dissolve the unprotected 
section of silver film (See Figure 3.11D). A one dimensional XEOL image was acquired 
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from the film before and after silver dissolution, and the XEOL was performed with and 
without placing a 1 cm thick section of pork tissue above the film.  The H2O2 etched area 
can be clearly identified by the increased luminescence, while it can be distinguished 
from the gold coated region with lower XEOL intensity. The gold coated region was 
unaffected by H2O2 providing a control strip. Most importantly, the resolution of the 
XEOL scan was hardly affected by the 1 cm of pork demonstrating that high resolution 
imaging through thick tissue. 
 
 
-2 0 2 4 6 8 10 12 14 16
20
40
60
80
100
120
In
te
n
s
it
y
X/mm
1.6mm
-2 0 2 4 6 8 10 12 14 16
20
40
60
80
100
120
In
te
n
s
it
y
X/mm
B
C
-2 0 2 4 6 8 10 12 14 16
100
200
300
400
500 1.7mm
In
te
n
s
it
y
X/mm
F
D
H2O2 etched area
A
Gold film Silver film
S
c
in
ti
ll
a
to
r
fi
lm
L
u
m
in
e
s
c
e
n
c
e
-2 0 2 4 6 8 10 12 14 16
100
200
300
400
500
In
te
n
s
it
y
X/mm
E
 56 
Figure 3.11 (A), (D) Images of gold and silver coated phosphor film before and after 
H2O2 etching. (B), (E) Intensity of red light scanned at different positions with/without 10 
mm of tissue before H2O2 etching. (C), (F) Intensity of red light scanned at different 
positions with/without 10 mm of tissue after H2O2 etching. The resolution through 10 mm 
tissue is 1.7 mm. Reproduced from Ref. 123 with permission from the Royal Society of 
Chemistry. 
Conclusion 
         We have extended the XEOL technique to tissue imaging where it offers a 
combination of high spatial resolution (limited by the X-ray beam width) and high 
sensitivity optical detection.  The high spatial resolution is competitive with conventional 
X-ray imaging but offers the ability to detect nanometer thick metal coatings and small 
changes in local absorption near indicator particles. Proof-of-principle involved detecting 
silver and gold nanoparticle patterns through 10 mm of pork as well as monitoring silver 
dissolution in H2O2, but the technique is general to a wide variety of indicator dyes and 
nanoparticle labels.  Interestingly, the high refractive index of the Gd2O2S phosphor 
increased the effective attenuation path length around the particle and also provided a 
method for label free detection of changes in local refractive index.   
          In future, the instrumentation can be enhanced using a narrower X-ray beam for 
higher spatial resolution imaging and using a multiple axis stage for two and three 
dimensional imaging.  In addition, higher sensitivity and more rapid signal acquisition 
can be realized with a modulated X-ray source and a photomultiplier tube with lock-in 
signal amplification (see Figure 3.4). An important application will be the non-invasive 
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detection of localized implant associated infection. We plan to use the technique to study 
bacterial products and inflammation markers, including hydrogen peroxide, oxygen, 
pH,
112
 quorum sensing molecules, and bacterial stains. Multiple analytes may be detected 
on spatially patterned sensors, as shown above using silver and gold nanoparticle patterns 
(see Figure 3.11). Alternatively, spectrally multiplexed sensing is possible using multiple 
rare-earth doped phosphors with narrow spectral peaks.  Relatively robust and long-lived 
sensors can be developed using inorganic materials, such as silver nanoparticles and 
hydroxyapatite, to monitor in situ chemical reactions through associated changes in local 
absorption and refractive index.  Overall, scanning XEOL provides new capabilities for 
chemical analysis in tissue and turbid media.   
Experimental Section 
Materials 
     Hydrogen peroxide aqueous solution (30% w/w) was purchased from BDH 
Chemicals Ltd (Poole, Dorset, UK). Europium doped Gadolinium oxysulfide 
(Gd2O2S:Eu) was purchased from Phosphor Technology Ltd. (Stevenage, UK) and it 
contained microparticles that ranged in size from 2~15 µm with a nominal diameter of 
8 µm.  Silver wire (>99.99%, 1 mm diam.) and gold wire (99.999%, 1 mm diam.) 
were purchased from Sigma-Aldrich (St Louis, MO, USA). Double sided tape (3M 
666, 1×1296 Inch) was purchased from 3M Company  (St. Paul, MN, USA). Cover 
glass (No. 0, 24×60 mm) was purchased from Electron Microscopy Sciences (Fort 
Washington, PA, USA). Immersion oil was purchased from Leica Microsystems 
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(Wetzlar, Germany). Deionized (DI) water was purchased from EMD Chemicals Inc. 
(Gibbstown, NJ, USA). Pork was purchased from Ingles Market, Inc. (Asheville, NC, 
USA). Reynolds Wrap Quality Aluminum Foil was purchased from Consumer 
Products Division of Reynolds Metal (Richmond, VA, USA). All chemicals were 
used as received without further purification.   
Preparation of the Gd2O2S:Eu phosphor film and coated with silver and gold nano-
film 
           A 24×60 mm cover glass was covered with double sided tape. A single layer of 
particles was attached to the surface of double-sided tapped by spreading 0.5 g europium 
doped gadolinium oxysulfide (Gd2O2S:Eu) powder on top of the tape. Excess particles 
were removed by rinsing in DI water, followed by drying at room temperature for 2hr. 
The sample was plasma etched for 5 min in a Harrick plasma etcher at media power in air 
plasma to make the surface hydrophilic. Finally the sample was coated with silver or gold 
using thermal vapour deposition.  
Nano-film of silver and gold coating and dissolution of the silver in hydrogen 
peroxide solution 
          The Gd2O2S:Eu film was coated with a thin layer of gold or silver.  The metal was 
deposited using thermal vapour deposition (Auto 360 vacuum coater/thermal evaporator, 
Edwards, West Sussex, UK) under high vacuum (< 5 × 10
−6
 Torr). The thickness of the 
metal was controlled using a shutter and measured with a quartz crystal microbalance. In 
order to study the rate of silver dissolution in H2O2, a Gd2O2S:Eu film was prepared with 
 59 
a 5 nm thick average coating of silver.  The film was then incubated in 1 mM H2O2 and 
the sample was taken out for luminescent spectra in every ten minutes. In order to 
selectively dissolve only a portion of silver in H2O2, a 5 nm silver film was masked with 
two strips of tape leaving an unmasked region between the two strips. The sample was 
then incubated in 1 mM H2O2 for 3 hr to dissolve the unmasked region. 
Instrumentation  
           An X-ray diffractometer (Rigaku; MiniFlex, Cu Kα ) was used as an X-ray source. 
For X-ray phosphor luminescence, the X-ray diffractometer was operated with tube 
voltage of 30 kV and tube current of 15 mA. The sample was mounted on a stepper motor 
stage (MTS 50, Thorlabs, Inc., Newton, NJ, USA) which was controlled by a program 
written in Labview (National Instruments, Austin, TX, USA).  To measure lifetime, the 
X-ray irradiation was modulated by an optical beam chopper equipped with a 1 mm thick 
aluminium chopper wheel (Stanford Research Systems, model SR540, CA). The intensity 
of the emitted light was measured with a PMT (R955, Hamamatsu Photonics, Japan) 
connected to Tektronix TDX 2004B Oscilloscope. The signal acquisition was triggered 
off of the chopper wheel photodiode. Data was transferred from the oscilloscope using an 
interactive measurement software v1.2 (NI SignalExpress Tektronix edition). The PMT 
was placed over a 0.5 cm thick piece of glass to block the small amount of scattered X-
ray photons while passing the visible luminescence. Scanning electron microscopy 
(SEM) was performed on a SU6600 microscope operated at 20 kV.   Luminescent and 
extinction spectra were acquired at room temperature with a FPC-400-0.22-1.5-UV fiber 
(Thor Labs) coupled photodiode array spectrometer (BRC741E-02 BWTEK Inc, Newark, 
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DE, USA).  Luminescent images were taken with a Nikon D90 digital camera with a 67 
mm diameter lens at 50 mm FL and a macro lens adaptor. To increase the captured 
luminescence, a 3×16 cm piece of aluminum foil was placed beneath the phosphor film.  
All the parameters of the camera were controlled by the software of Camera Control Pro2 
(Nikon Instruments Inc., Melville, NY, USA). All images were analyzed using Matlab 
R2009b. 
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                                                      CHAPTTER FOUR 
IV. MONITORING PH-TRIGGERED DRUG RELEASE FROM 
RADIOLUMINESCENT NANOCAPSULES WITH X-RAY EXCITED OPTICAL 
LUMINESCENCE 
Introduction 
         Doxorubicin (DOX) is a chemotherapy drug used to treat a wide range of cancers. 
However, its serious adverse effects such as suppression of hemaropoiesis, 
gastrointestinal and cardiac toxicity limit its applications.
113-114
 It is crucial to control the 
concentration of doxorubicin specifically in the blood circulation, normal tissues, and 
tumor tissues. Unfortunately, DOX clears rapidly from circulation (circulation half-life of 
< 5 min)
115
 which makes it difficult to specifically target tumor cells using free drug. A 
pH- responsive controlled system for DOX could address this issue by releasing drugs 
into the blood only gradually, but rapidly release drugs after endocytosis in acidic tumor 
lysosomes and endosomes. The particles could be targeted to tumors via enhanced 
permeability and retention (EPR) effect and by functionalizing the nanoparticle surface 
with appropriate antibodies or other targeting molecules. In 2005, Lee et al. reported pH-
sensitive micelles as carriers for DOX to enhanced tumor specificity and endosome 
disruption property on the carrier.
116-117
 Recently, mesoporous silica has gained attention 
as drug storage and release hosts due to their textural properties and easily modified 
surface.
118-121
 Zhu and co-workers reported pH-controlled delivery of DOX to cancer 
cells based on small mesoporous carbon nanospheres. In our previous work, a ratiometric 
pH sensor based on the ratio of certain radioluminesence peaks of terbium doped 
gadolinium oxysulfide (Gd2O2S:Tb) was developed.
112
 The ratio of luminescent spectral 
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peaks is independent of the luminescence intensity which provides a promising method to 
detect chemicals in tissue with high spatial resolution with a narrow scanning X-ray beam 
and selectively exiting the phosphor film by taking advantage of the excellent penetration 
of X-ray beam in tissue and wide range of availability of X-ray phosphors.
122
 Xing group 
and we found that changes in spectrum and intensity can be imaged through tissue at a 
resolution dictated by the X-ray beam,
54-55, 123
 and we have demonstrated submilimeter 
imaging through 1 cm of chicken breast.
112, 124
 We also demonstrated that the XEOL 
spectrum of hollow Gd2O3:Eu nanoparticles is greatly reduced by the presence of an iron 
oxide core,
125
 and the luminescence of solid Gd2O2S:Eu particles is modulated by the 
absorption spectrum of silver nanoparticles on the phosphor surface.
123
 Based upon these 
results, we hypothesized that we could monitor release of dyes and optically absorbing 
drugs from the core of nanocapsules. 
          In this work, we synthesize rare-earth (Tb, Eu) doped Gd2O2S based 
radioluminescent capsules as a drug nanocarrier and drug release monitor. Compared 
with gadolinium oxide doped with Eu, Tb and Eu doped gadolinium oxysulfide possesses 
higher photo conversion efficiency (60,000 visible photons/MeV for Gd2O2S:Tb, and 
Gd2O2S:Eu, 40,000 visible photons/MeV for Gd2O3:Eu).
124
 Their bright 
radioluminescence (Figure 4.1) can be used to track the delivered drug (DOX) and 
monitor the drug release process. Meanwhile, these capsules serve as good T2-weighted 
MRI contrast agent which can be used as a complementary imaging mode for X-ray 
functional imaging.
126
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Results and discussion 
          Particle shape plays a crucial role in the application of drug delivery systems.
127-128
 
Some previous studies on particles with high aspect ratio (e. g. nanorod, nanorice) 
showed that those particles (> 500 nm in length) with high aspect ratio have slower 
clearance rate compared with particles with low aspect ratio (e.g. spherical particles) in 
the application of drug delivery systems.
129-130
 To demonstrate the shape effect on the 
clearance rate for the future study, we chose ellipsoidal hollow silica nanorice as 
templates to synthesize monodispersed ellipsoidal nanocapsules. In addition, by varying 
the synthesis condition of template,
131-133
 the length of these nanocapsules are can be 
tuned from 20 nm to 600 nm and the aspect ratio can be adjusted from spheres to prolate 
spheroids. In order to obtain monodispersed silica nanoshells, as shown in Figure 4.2, 
monodispersed hematite nanorice is first prepared, then treated through a modified Stöber 
procedure to form a thin silica shell. Finally the hematite core was removed by etching in 
0.5 M oxalic acid for 17 h. The uniform and negatively charged silica shell were then 
coated with a layer of positive charged Gd2O(CO3)2•H2O doped with terbium (Tb
3+
, 2.4% 
mol) or europium (Eu
3+
, 5.1% mol) through a homogeneous precipitation method from 
gadolinium, europium nitrate. This method employs an electrostatic interaction between 
negative charged silica shell and positive charged radioluminescent shell.
125
 After heat 
treatment at 600 °C for 1 h, the amorphous Gd2O(CO3)2•H2O layer transformed into 
Gd2O3. The above product was treated by sulphur gas with argon flow at 900 °C for 1h to 
convert the Gd2O3 to Gd2O2S. The obtained nanoparticles was re-heated at 400 °C in the 
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air for 1h and incubated in boiling water for 2 h to remove the residue of sulphur and 
gadolinium sulphide.     
           TEM images in Figure 4.3A show monodispersed spindle-shaped iron oxide seeds. 
Figure 4.3B represents the intact silica shell after the iron oxide core was removed by 
dissolving in oxalic acid. The SEM image in Figure 4.3C and narrow size distribution in 
Figure 4.3D indicate the monondispersed nanocapsules were obtained successfully with 
an average length of 420 +/-20 nm and width of 130 nm +/-15 nm. The nanocapsules 
possess a 10 nm thick inner silica shell and a 25 nm thick outer Gd2O2S:Tb 
radioluminescent shell (Figure 4.3F) with porous morphology (Figure 4.3E, F and Figure 
4.4,). The pores are irregular in shape, with an average diameter of (8.5 +/- 2 nm). These 
visible pores in the shell (Gd2O2S:Tb) of the nanocapsules likely facilitate drug loading 
and releasing. Crystal structure and composition of these nanocapsules were 
characterized by powder X-ray diffraction (XRD) and the host is shown as hexagonal 
phase of Gd2O2S according to the data of JCPDS card no. 26-1422 (Figure 4.5). 
Gd2O2S:Eu with similar aspect ratio were also synthesized by the same silica 
nanotemplate (Figure 4.6). The tunable size range and the morphology make these 
nanocapsules promising as drug carriers. In order to apply these nanocapsules in 
biological applications, the stability of the nanocapsules was tested in 0.3 % (v%) acetic 
acid (pH ~3.0). The SEM images in Figure 4.7 show no discernible dissolution indicating 
that the nanocapsules are very stable under pH 3 at 37 °C even after 24 hr. The cell 
viability of our X-ray phosphors on MCF-7 breast cancer cells is also tested and it’s 
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shown that cell viability is greater than 90% when the concentration of Gd2O2S:Tb and 
Gd2O2S:Eu is as high as 250 µg/ml, after incubation for 24 h (Figure 4.8). 
 
 
 
 
Figure 4.1 X-ray luminescence of (A) Gd2O2S:Tb and Gd2O3:Tb nanocapsules, inserted 
figure shows the spectrum of Gd2O3:Tb in high magnification, (B) Gd2O2S:Eu and 
Gd2O3:Eu nanocapsules. Photograph of Gd2O2S:Tb, Gd2O3:Tb, Gd2O2S:Eu, and 
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Gd2O3:Eu under X-ray (C). Reprinted with permission from ref. 126. Copyright 2012 
American Chemical Society 
 
 
Figure 4.2 Schematic illustration of the synthesis of radioluminescent nanocapsules. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
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Figure 4.3 (A) TEM image of monodispersed iron oxide seeds, (B) TEM image of hollow 
silica shell after removing iron oxide core, (C) SEM image of monodispersed 
radioluminescent nanocapsule (Gd2O2S:Tb (Tb/Gd=2.4% mol), (D)  Size distribution of 
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the nanocapsules, (E) High magnification SEM image of nanocapsule, (F) TEM image of 
the nanocapsule, (G) High magnification SEM image of surface of a nanocapsule, (H) 
pore size distribution from 100 nanocapsules. Reprinted with permission from ref. 126.  
Copyright 2012 American Chemical Society. 
 
 
Figure 4.4 SEM image showing the porous and hollow nanocapsules (Gd2O2S:Tb). 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
 
100 nm
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Figure 4.5 XRD patterns of (A) Gd2O(CO3)2•H2O:Tb, (B) Gd2O3:Tb, (C) Gd2O2S:Tb. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society 
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Figure 4.6 SEM (A) and TEM (B) images of nanocapsule (Gd2O2S:Eu, Eu/Gd=5.1% 
mol), (C) size distribution of nanocapsules (Gd2O2S:Eu). Reprinted with permission from 
ref. 126.  Copyright 2012 American Chemical Society. 
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Figure 4.7 XRD patterns of (A) Gd2O(CO3)2•H2O:Eu, (B) Gd2O3:Eu, (C) Gd2O2S:Eu. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
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Figure 4.8 Cytotoxicity test of nanocapsules (Gd2O2S:Tb and Gd2O2S:Eu) and PSS/PAH 
multilayers coated nanocapsules (Gd2O2S:Tb). Reprinted with permission from ref. 126.  
Copyright 2012 American Chemical Society. 
 
           The radioluminescence spectra of nanocapsules (Gd2O2S:Tb, Eu) are presented in 
Figure 4.9. The radioluminescence mechanism involves the generation of electron-hole 
pairs in the host lattice following X-ray absorption. These electron-hole pairs then excite 
Tb
3+
 and Eu
3+
 centers which emit visible and near infrared light. The conversion 
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efficiency is 60,000-70,000 visible photons/MeV X-ray photon in bulk Gd2O2S:Eu, 
corresponding to an energy efficiency of 15%.
22, 36, 134
 The narrow luminescent peaks of 
Gd2O2S:Tb are attributed to the transitions from the 
5
D4 excited-state to the 
7
FJ (J=6, 5, 4, 
3, 2, 1, 0) ground states of the Tb
3+
 ion. The 
5
D4
7
F5 transition at 544 nm is the most 
prominent group. The 
5
D0,1
7
FJ (J=0, 1, 2, 4) transition lines of the Eu
3+
 ions generate 
the intense peak at 590, 612, 620, 720 nm. The strongest red emission which splits into 
two peaks at 621 and 612 nm arises from the forced electric-dipole 
5
D0
7
F2 transitions of 
the Eu
3+
 ions. These nanocapsules displayed similar fluorescence spectra under blue 
excitation light (460-495 nm) (Figure 4.10). However, blue light does not penetrate as 
deeply into tissue as X-rays, and unlike X-rays, does not stay collimated or focused 
which dramatically reduces image resolution. 
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Figure 4.9 X-ray luminescence of nanocapsules. (A) Gd2O2S:Tb, (B) Gd2O2S:Eu. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
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Figure 4.10 Fluorescence spectra of nanocapsules (Gd2O2S:Tb and Gd2O2S:Eu) excited 
by 460 to 495 nm light. Reprinted with permission from ref. 126.  Copyright 2012 
American Chemical Society. 
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Figure 4.11 (A) schematic illustration of the synthesis of DOX@Gd2O2S:Tb@PSS/PAH 
and pH-responsive release of DOX. Low magnification (B) and high magnification (C) 
TEM image of DOX@Gd2O2S:Tb@PSS/PAH. Reprinted with permission from ref. 126.  
Copyright 2012 American Chemical Society. 
 
            Styrenesulfonate sodium (PSS) and poly(allylamine hydrochloride) (PAH) are 
widely used polyelectrolytes in pH-controlled release systems.
135-138
 In order to create a 
stimuli-responsive system for DOX, our X-ray luminescent nanocapsules coated with 
100 nm500 nm
SiO2
100 nm500 nm
CB
SiO2 Gd2O2S:Tb
PSS/PAH multilayers
A
 77 
eight layers of negative charged PSS and seven layers of positive charged PAH to 
encapsulate DOX with layer by layer assembly (Figure 4.11; the particle is denoted as 
DOX@Gd2O2S:Tb@PSS/PAH). Due to the surface of our nanocapsules are positive 
charged (+14.9 mV, Figure 4.12), the first layer of polyelectrolyte coated on 
nanocapsules is PSS. After the layer by layer coating, the nanocapsules are coated by an 
average of 30 nm thick polyelectrolyte with a layer of PSS on the surface. Cell viability 
test indicates that the empty Gd2O2S:Tb nanocapsules coated with PSS/PAH multilayers 
show no significant toxicity to a concentration of at least 250 µg/ml, the highest 
concentration measured (Figure 4.8). In order to demonstrate the DOX is loaded into the 
nanocapsules, nanocapsules filled with solid core were synthesized as a control by using 
the silica coated hematite instead of hollow silica shells as the template.  The same DOX 
loading and polyelectrolyte coating were employed to the nanocapsules with a solid core 
(iron sulfide). From the released DOX from these solid particles, we calculate that the 
hollow particles release approximately 20× more DOX than the solid-core particles, 
indicating that most of the DOX is stored in the core of the hollow particles (Figure 4.13). 
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Figure 4.12 Zeta potential of Gd2O2S:Tb nanocapsules. Reprinted with permission from 
ref. 126.  Copyright 2012 American Chemical Society. 
               To study the release rate at normal physiological pH and in acidic cancer 
environments, we measured the release rate in pH 7.4 PBS and 5.0, respectively. The 
cumulative release profile of doxorubicin from these nanocapsules is pH-dependent 
(Figure 4.14). The drug release is enhanced at pH 5.0 which is applicable for cancer 
therapy due to the low pH environment in tumor endosomes. Based upon exponential 
fitting to the HPLC release curve, the release rate time constant was estimated to be ~ 36 
days at pH 7.4, and 21 hr at pH 5.0. From the released DOX at pH 5.0 after 48 h, the 
encapsulated DOX in DOX@Gd2O2S:Tb@PSS/PAH was over 5% by weight. The 
luminescence peak ratio at 544 nm and 620 nm is used to track the release of DOX 
(Figure 4.14B). The release rate time constant was estimated to be ~ 7 days at pH 7.4, 
and 4 hr at pH 5.0. The radioluminescence peak ratio is shown to be very sensitive to the 
release of DOX in the first 10 hr. 
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Figure 4.13 (A) PSS/PAH coated multilayers of nanocapsules with solid core, (B) 
absorbance of cumulative DOX released of hollow nanocapsules and nanocapluses with 
solid core at pH 2. Reprinted with permission from ref. 126.  Copyright 2012 American 
Chemical Society. 
Figure 4.14 (A) Cumulative release of doxorubicin from DOX@Gd2O2S:Tb@PSS/PAH 
at pH 5.0 and 7.4, (B) peak ratio of real time radioluminescence detection at 544 and 620 
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nm as a function time in pH 5.0 and pH 7.4. The data fits to a single exponential. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
 
Figure 4.15 (A) Absorption of DOX (0.05 mg/ml at pH 5.0 and 7.4) and 
radioluminescence of Gd2O2S:Tb@PSS/PAH, (B) real-time radioluminescent spectra of 
DOX@Gd2O2S:Tb@PSS/PAH at pH 5.0. Reprinted with permission from ref. 126.  
Copyright 2012 American Chemical Society. 
 
        Our pH-responsive controlled release system is also able to monitor the release 
process of DOX at different pH by detecting the radioluminescence of Gd2O2S:Tb 
nanocapsules (Figure 4.15B). At pH 5.0 and 7.4, DOX has a similar broad absorption of 
light from 350 to 600 nm which overlaps with some of the XEOL peaks of Gd2O2S:Tb 
(Figure 4.15A). Figure 4.15B shows the intensity ratio of X-ray luminescence at 544 nm 
and 620 nm increases with the release of doxorubicin because local luminescence 
absorption by DOX decreases when DOX is released. We observed the similar 
luminescent increase of nanoparticle with iron oxide as a core when the iron oxide are 
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partially dissolved.
125
 The peak intensity ratio reaches a maximum value when the DOX 
concentration in the particles is in equibilibrium with the solution concentration.  
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Figure 4.16 (A) Photograph of MCF-7 breast cancer cells with and without internalized 
nanocapsules (Gd2O2S:Eu) under room light and X-ray irradiation.  Transmitted 
differential intereference contrast microscopy (B) and fluorescence image (C) of MCF-7 
cells with internalized nanocapsules (Gd2O2S:Eu), (D) Merged image of (B) and (C). 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
             In order to examine the uptake of these nanocapsules by cancer cells, 
nanocapsules doped with europium (Gd2O2S:Eu) were incubated with MCF-7 cancer cell 
and washed multiple times to eliminate nanocapsules from the cell culture media. The 
internalized nanocapsules were brightly luminescent under X-ray radiation (Figure. 
4.16A). The bright fluorescence signal of nanocapsules is very useful in drug localization 
and cell labeling. Figure 4.16C shows the fluorescence signal of the Gd2O2S:Eu 
nanocapsules in MCF-7 cancer cell after multiple washing step to eliminate nanocapsules 
from the cell culture media. 
     To demonstrate that the nanoparticle XEOL can be imaged in vivo using a IVIS 
Lumina-XR Imaging System (Caliper Life Sciences, Hopkinton, MA, US) during 
irradiation with miniature X-ray source (Amptek Mini X-ray tube, Ag target, Amptek  
Inc. MA, USA), 200 µL of 1 mg/mL Gd2O2S:Eu nanocapsules coated with PSS/PAH 
multilayers were inject into a mouse tail vein. The effective nanocapsule concentration in 
the mouse is about 133 μg/ml (the blood volume of a mouse is around 1.5 ml) which did 
not affect cell viability for MCF7 breast cancer cells in vitro. Furthermore, a preliminary 
Maximum Tolerated Dose (MTD) study was carried out and it shows no morbidity or 
weight loss was observed for doses up to 400 mg/kg. The in vivo accumulation of the 
 83 
nanocapsules in the liver was evident under X-ray irradiation with 0.1 s exposure time. 
Compared to the Gd2O2S:Eu without PSS/PAH mutilayers (Figure 4.17), the 
accumulation rate for polyelectrolytes coated nanocapsules is slower in the first 1 h. Post 
mortem, XEOL images of the excised organs confirmed that the nanocapsules 
accumulated in liver and spleen (Figure 4.18).  
 
 
 
 
 
Figure 4.17 Representative luminescent images of accumulation of Gd2O2S:Eu 
nanocapsules with and without polymer coating in mouse. (A) 5 min, (B) 1 h, (C) 6 h, 
(D) 24 h after the mouse was injected with saline (200 µl).  (E) 5 min, (F) 1 h, (G) 6 h, 
(H) 24 h after the mouse was injected with Gd2O2S:Eu@PAH/PSS nanocapsules (200 
µl, 1 mg/ml). (I) 5 min, (J) 1 h, (K) 6 h, (L) 24 h after the mouse was injected with 
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Gd2O2S:Eu nanocapsules (200 µl, 1 mg/ml).  (M) Total radioluminescent intensity 
counts as a function of time after injection. Reprinted with permission from ref. 126.  
Copyright 2012 American Chemical Society. 
 
 
Figure 4.18 Representative radioluminescent images of accumulation of Gd2O2S:Eu 
nanocapsules with and without polymer coating in organs after 24 h. (A) Brain, (B) 
Kidney, (C) Heart, (D) Fat, (E) Liver, (F) Lung, (G) Spleen, and (H) Muscle in the saline 
injected mouse. (I) Brain, (J) Kidney, (K) Heart, (L) Fat, (M) Liver, (N) Lung, (O) 
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Spleen, and (P) Muscle in the Gd2O2S:Eu@PAH/PSS nanocapsules (200 µl, 1 mg/ml) 
injected mouse. (Q) Brain, (R) Kidney, (S) Heart, (T) Fat, (U) Liver, (V) Lung, (W) 
Spleen, and (X) Muscle in the Gd2O2S:Eu nanocapsules (200 µl, 1 mg/ml) injected 
mouse. Reprinted with permission from ref. 126.  Copyright 2012 American Chemical 
Society. 
 
Figure 4.19 The magnetic hysteresis loops of (A) Gd2O2S:Tb and (B) Gd2O2S:Eu. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
       Recent studies describe the synthesis and applications of gadolinium oxide 
(Gd2O3) nanoparticles as MRI contrast agents.
125, 139-143
 However, to our knowledge, no 
investigation of gadolinium oxysulfide based MRI contrast agents are reported so far. 
Our luminescent nanocapsules mainly consisting of gadolinium oxysulfide (Gd2O2S) also 
have similar magnetic properties with gadolinium oxide which make them a potential 
MRI contrast agent and magnetic separation tool. The room temperature magnetic 
hysteresis loops of nanocapsules (Gd2O2S:Tb, Gd2O2S:Eu) are shown in Figure 4.19. As 
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the strength of the applied magnetic field increased, the linear correlation between the 
magnetization and the applied magnetic field indicates the both Gd2O2S:Tb and 
Gd2O2S:Eu nanocapsules are paramagnetic, with minimal hysteresis and a magnetic 
susceptibility of 1.2×10
-4
 emu g
-1
 Oe
-1 
and showed no sign of saturation up to applied 
fields of 30 kOe. 
          We performed in vitro MR assays (T2 and T2* weighted imaging) in 0.5% agarose 
gel for both types of Gd2O2S:Tb and Gd2O2S:Eu nanocapsules with a series of 
concentration (0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml). Figure 4.20 shows T2 
and T2* weighted images after 3 ms. the proton relaxivities r2 of the nanocapsules was 
determined from the longitudinal and transverse relaxation rates at various 
concentrations. These relaxation rates are shown as a function of concentration in Figure 
4.21. The relaxivities, r2 and r2* are 50.3 mM
-1
s
-1
 and 116.0 mM
-1
s
-1
 respectively for 
Gd2O2S:Tb nanocapsules; 51.7 mM
-1 
s
-1
 and 116.4 mM
-1
s
-1
 for Gd2O2S:Eu nanocapsules.
Figure 4.20 T2 and T2*-weighted images of radioluminescent nanocapsules. Group A: 
T2-weighted images of Gd2O2S:Eu nanocapsules with concentration of 0.8 mg/ml, 0.4 
mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B: T2-weighted images of Gd2O2S:Tb with 
concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group A*: T2*-
weighted images of Gd2O2S:Eu nanocapsules with concentration of 0.8 mg/ml, 0.4 
A
B
3 ms 3 ms
0.05 0.10.40.8 H2O 0.10.40.8 0.05 H2O
A*
B*
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mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B*: T2*-weighted images of Gd2O2S:Tb 
nanocapsules with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. 
Reprinted with permission from ref. 126.  Copyright 2012 American Chemical Society. 
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Figure 4.21 MRI T2 and T2* relaxation rate curves as a function of Gd2O2S:Tb (A, C) and 
Gd2O2S:Eu (B, D)  concentration. Reprinted with permission from ref. 126.  Copyright 
2012 American Chemical Society. 
           For these nanocapsules, r2* is larger than r2 due to the inhomogeneities of local 
static field from the magnetic moment of the particles. Previous work towards the 
gadolinium nanoparticles (e. g. ultrasmall Gd2O3 nanoparticles (1~10 nm)
139-142
 and 
hollow nanosparticles with thin Gd2O3 shell (~10 nm)
143
) reported that they can served as 
good T1 contrast agents and moderate T2 contrast agents. However,  our nanocapsules 
with a ~25 nm Gd2O2S based nanoshell worked as a better T2 contrast agents compared 
with Gd2O3 nanoparticles (r2=14.1~16.9 mM
-1
s
-1
)
144-146
 and gadolinium chelates (Gd-
DTPA, 4.9 mM
-1
s
-1
)
144
 compared with some In addition, the T2 relaxivities value of our 
nanocapsules has similar value with some FDA-approved iron oxide nanoparticle contrast 
agents such as Ferumoxtran (Resovist®, 65 mM
-1
s
-1
), cross-linked iron oxide particle 
(CLIO-Tat, 62 mM
-1
s
-1
), and water soluble iron oxide (WSIO, 78 mM
-1
s
-1
).
147-150
  
Conclusion 
           In summary, we present a flexible template-directed method to produce 
radioluminescent nanocapsules for a hydrophilic drug carrier and monitor release kinetics. 
The release rate time constant was ~ 36 days at pH 7.4, and 21.4 hr at pH 5.0, 
respectively. Importantly, the release mechanisms could be monitored in situ by tracking 
the ratio of readioluminescence spectral peaks. Radioluminescence offers several 
advantages over traditional optical imaging agents, including greater tissue penetration, 
 89 
elimination of autofluorescence, and the ability to perform high-resolution imaging 
through thick tissue via functional X-ray Luminescence Tomography (FXLT)
54-55, 112, 123
. 
Finally, the multifunctional nanocapsules combined the advantages of positive contrast of 
radioluminescence and negative contrast of T2 weighted MR imaging. These capabilities 
provide these nanocapsules to enable novel drug delivery and imaging modalities. In 
future, we plan to target DOX loaded capsules to tumors and measure in situ release rates 
and tumor growth for various nanocapsule sizes, shapes, and surface chemistries. 
Experimental Section 
Materials 
         Tetraethoxysilane (TEOS), poly(styrenesulfonate sodium) (PSS, MW:~70,000), 
Iron (III) chloride anhydrous was purchased from Sigma-Aldrich (St. Louis, MO). 
Gadolinium nitrate, europium nitrate, and poly(allylamine hydrochloride) (PAH, 
MW:~15,000) were purchased from obtained from Alfa Aesar (Ward Hill, MA).  Ethanol 
(96%), urea, oxalic acid, ammonium hydroxide, and nitric acid were obtained from BDH 
Chemicals Ltd (Poole, Dorset, UK). Deionized (DI) water was purchased from EMD 
Chemicals Inc. (Gibbstown, NJ, USA). Polyvinylpyrrolidone (PVP K-30, MW 40,000) 
was purchased from Spectrum Chemicals (Gardena, CA). Agarose (melting point 88±1 
ºC) was purchased from Shelton Scientific (Peosta, IA). All chemicals were used as 
received without further purification.   
In vitro HPLC drug-release study and real-time drug release tacking: 100 µl of DOX 
encapsulated nanocapsules with polyelectrolyte mutilayers (10 mg/ml) were suspended 
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with release media (7 ml) at pH 5.0 and 7.4 in Slide-A-Lyzer MINI dialysis units at room 
temperature. The release medium was removed for analysis at given time intervals, and 
replaced with the same volume of fresh release medium. The DOX concentration was 
measured with high performance liquid chromatography (HPLC) on a Waters system 
using an Alltima C18 column (250×4.6 mm, 5 µm). 
Radioluminescence drug release tracking experiment: 2 ml DOX encapsulated 
nanocapsules with polyelectrolyte multilayers (25 mg/ml) were magnetically stirred at a 
rate of 400 rpm in release media of either pH 5 or pH 7.4. 50 µl of the solution was taken 
out for X-ray luminescence analysis without any separation at given time intervals. 
Preparation of nanocapsules for MR Imaging: T2 and T2* MR measurements were 
acquired for the spindle-shaped SiO2@Gd2O2S:Eu and Gd2O2S:Tb particles at a series of 
concentrations (0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml).  The particles were 
dispersed in 0.5% agarose gel at 80 °C and cooled to room temperature in NRM tubes to 
set the gel. The gel prevented settling and aggregation allowing MRI imaging several 
days after preparation.  
Cell viability test: MCF-7 breast cancer cells were seeded at a density of 10,000 
cells/well in a 96-well plate.  Cells were stored at 37 °C at 5% CO2 and attached to the 
plate overnight.  Nanocapsules were suspended in media, sonicated for 10 minutes to 
disperse, and diluted to 250, 100, 50, and 10 µg/ml.  Media was removed from wells and 
fresh media or nanoparticle in media was added to each well. Five repeats were done for 
each concentration.  Nanoparticles were incubated with cells overnight and the next day a 
Presto Blue assay (Life Technologies) was performed. Media was removed and 100 µl of 
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a 1:9 ratio Presto Blue in culture media was added to each well.  Cells were incubated at 
37 °C and 5% CO2 for 45 minutes. Fluorescent intensity was taken with a plate reader 
with an excitation wavelength of 560 nm and an emission wavelength of 590 nm. 
Fluorescent intensity for each concentration of nanoparticle was normalized as a 
percentage of the fluorescent intensity of the control cells. Percent viability averages 
were plotted with error bars of one standard deviation.   
Characterization methods: Transmission and scanning electron microscopy (TEM) 
were performed on a H9500 operated at 200 kV and HD2000 microscope operated at 20 
kV, respectively. Powder XRD patterns were obtained on a Rigaku diffractometer at 40 
kV and 40 mA (CuKα radiation). For fluorescence spectra, 480 nm light was used to 
excite the phosphors. To measure radioluminescence, X-ray was generated by a mini X-
ray tube (Amptek Inc. MA, USA), the X-ray tube was operated with tube voltage of 40 
kV and tube current of 40 mA. The sample was mounted on a Leica Microscope (Leica 
DMI 5000M, Wetzlar, Germany) equipped with a DeltaNu DNS 300 spectrometer 
(Intevac-DeltaNu, Laramie, WY USA) with a 150 lines/mm grating blazed at 500 nm and 
with a cooled CCD camera (iDUS-420BV, Andor, South Windsor, CT). X-ray 
luminescence images were captured with an IVIS Lumina-XR Imaging System (Caliper 
Life Sciences, Hopkinton, MA, US). Bright field and fluorescent images were taken on a 
Nikon microscope (Eclipse Ti, Nikon, Melville, NY USA). Determination of the Zeta-
potential of the nanoparticles was performed via a Zetasizer Nano ZS (with a 633 nm He-
Ne laser) from Malvern Instrument. Prior to the experiment, the particles were diluted in 
distilled water (0.1 mg/ml). Magnetization measurements were performed at the 
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designated temperature using vibrating sample magnetometer (VSM) option of physical 
property measurement system (PPMS, Quantum Design, USA), with the applied 
magnetic field sweeping between +/- 3.0 Tesla at a rate of 50 Oe/sec. Determination of 
the gadolinium content in a sample was performed by inductively coupled plasma (ICP)- 
(Optima 3100 RL; Perkin-Elmer). All MRI experiments were performed on a Varian 
4.7T horizontal bore imaging system (Agilent Inc, Santa Clara, CA).  Samples, contained 
in 5 mm NMR tubes, were placed in a 63 mm inner diameter quadrature RF coil for 
imaging. 
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                                                        CHAPTTER FIVE 
V.  MAGNETIC AND OPTICAL PROPERTIES OF MULTIFUNCTIONAL 
CORE-SHELL RADIOLUMINESCENCE NANOPARTICLES   
Introduction 
        Multifunctional magnetic and fluorescent nanomaterials have attracted broad interest 
because of their utility in biomedical applications such as bioimaging,
151
 drug delivery 
carriers,
152
 magnetic resonance imaging (MRI),
153
 bio-separation,
154
 fluorescent 
labeling,
155-156
 magnetic hyperthermia,
157
 and immunoassays.
158
 These magnetic particles 
can be magnetically guided, oriented, heated, and imaged using external magnetic fields. 
Meanwhile the particle fluorescence provides a sensitive label for imaging in cells and 
thin tissue sections. 
          Although biological tissues are essentially transparent to magnetic fields which 
facilitates in vivo magnetic control and imaging, fluorescence measurements are limited 
in thick tissue due to autofluorescence backgrounds and optical scattering. X-ray 
luminescence tomography (XLT) addresses these issues by using radioluminescent 
contrast agents for low background, high resolution imaging in tissue.
42, 159
 
Radioluminescence is well-suited for tissue imaging because both the X-ray excitation 
and near-infrared (NIR) emission penetrate deeply through tissue and because unlabeled 
tissues display minimal radioluminscence backgrounds. XLT images are generated by 
scanning a narrow X-ray beam relative to the sample and detecting the diffuse light 
escaping from the tissue using sensitive photodetectors. By restricting the X-ray 
excitation to a single narrow beam, the origin of the optical photons can be inferred 
 94 
regardless of how many times these photons scatter in tissue and where they emerge from 
the tissue. This enables tomography with a resolution limited by the X-ray beam width in 
the tissue. The principle is similar to scanning confocal and structured illumination 
optical microscopies, except that while multiphoton confocal microscopy is limited to 
tissue thicknesses of 1 mm or less,
82
 XLT can image through several centimeters of tissue 
because the X-rays are far less scattered than visible and NIR light. With a 1 mm X-ray 
beam and 1–100 cGy radiation dose, Pratx et al. achieved a spatial resolution of 1 mm 
through tissue-mimicking material based on the selective excitation of subpicomolar of 
50 nm phosphor and optical detection of their luminescence.
42
 They also showed that 
XLT could image the cross sectional distribution of microsize phosphor particles in 4.5 
cm of an agar tissue phantom.
41
  
         Previously, we extended the XLT technique towards functional chemical imaging 
on implanted phosphor films using X-ray excited optical luminescence as a local light 
source for absorption spectroscopy of indicator dyes on the film surface. We developed a 
radioluminescent pH-sensing film based upon indicator dye absorption, and demonstrated 
0.3 mm knife-edge resolution imaging through 1 cm of chicken.
112
  We also imaged 
patterns of silver deposition and dissolution on a phosphor film through 1 cm of pork 
tissue.
123
 Our technique is uniquely suited for studying chemical changes on the surface 
of implanted medical devices. The principle can also be extended to the third dimension 
for using particles with indicator dyes. 
          Herein, we developed a novel and facile strategy to fabricate magnetic phosphors 
for MRI and XLT imaging. Magnetic fluorescent and upconversion nanoparticles have 
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previously been reported with an iron oxide core and rare earth doped NaYF4:Yb,Er 
shell.
160-161
 However, a challenge is that iron oxide quenches most of the fluorescence if it 
contacts the phosphor or is in proximity, even with a thin silica spacer layer.
162-165
 This 
demonstrates that absorption in the core modulates the luminescence signal, which would 
be a useful feature for generating chemical sensors with encapsulated indicators. 
However, the iron oxide core decreases the luminescence intensity and leaves no space 
for encapsulating drugs or dyes. In order to increase the luminescence intensity, we 
partially etched the iron oxide core in oxalic acid. The particles’ optical and magnetic 
properties depend upon the core size, which in is controlled by varying the etching time. 
The etching process also produced a hollow space around the core which could be used 
for drug and dye encapsulation.   
Results and discussion 
         Our objective was to synthesize radioluminescent particles with controllable size, 
shape, optical, and magnetic properties. We selected europium-doped gadolinium oxide 
as a matrix because of its photostablity,
166
 its narrow and distinct spectral features under 
fluorescence and radioluminescence,
167-168
 its MRI contrast,
139-140, 142-143, 169
 and its 
relatively non-toxicicity.
140, 142-143
 We selected a core-shell template synthesis route so 
that we could separately control the magnetic core and luminescent shell materials. Our 
initial studies employed spindle-shaped hematite cores and therefore generated spindle-
shaped shells. However, the shape of the shell can be altered by using different core 
shapes by changing the hematite synthesis conditions.
132-133, 170
 Although macrophage 
uptake of particles with diameters larger than 500 nm reduces circulation time and is an 
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obstacle to particulate drug delivery,
171
 there are some reports that changes in particle 
shape strongly affect macrophage uptake and biodistribution. For example, Huang and 
Decuzzi et al. studied the clearance of a series of non-spherical silica/silicon 
nanoparticles with a length range of 300 nm~5 µm and observed that the particle shape 
plays a crucial role in the circulation lifetime and biodistribution which are important for 
drug delivery applications.
127-128, 130
 Champion and co-workers recently found that 
macrophages internalize ellipsoid particles 2~6 µm long in a strongly orientation-
dependent manner. They observed that it took only a few minutes to internalize particles 
with the high radius of curvature region contacting the macrophages, while particles 
contacting the macrophages on their low curvature sides were not internalized within 12 
h.
129
   Our long term goal will be to study how shape and size affect the biodistribution 
using in situ XLT imaging.  
 
Structure and morphology of magnetic luminescent nanoeyes (γ- 
Fe2O3@SiO2@Gd2O3:Eu) 
          The template core-shell synthesis process is presented in Figure 5.1. We first 
synthesized a monodispersed spindle-shaped hematite core according to methods 
described by Ozaki and co-workers.
[21]
 Our particles were spindle shaped with an average 
length of 400 nm and diameter of 80 nm, however, by varying the synthesis conditions, 
the nanoparticle size can be tuned from 120 to 550 nm, and the aspect ratio from spheres 
to prolate spheroids.
132, 170
 Hematite is a chemically stable antiferromagnetic phase of 
iron oxide which can be later reduced to magnetite or iron and oxidized to ferrimagnetic 
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maghemite (γ-Fe2O3). Hematite is used as a template because it is difficult to directly 
synthesize uniform spindle magnetite or maghemite particles, and these large particles 
often aggregate in magnetic fields especially at high particle concentration. The colloidal 
hematite particles had a positive zeta potential of +26 mV which kept them well 
dispersed in solution due to electrostatic repulsion. This positively charged hematite 
could not be directly used as template for growing a phosphor shell because the positively 
charged hematite would repulse the positively charged phosphor precursor 
(Gd2O(CO3)2:Eu, +11 mV), see Figure 5.2. Instead, the hematite nanoparticles were first 
treated through a modified Stöber procedure
172
 to deposit a thin silica layer which 
reversed the surface charge (-36 mV), see Figure 5.3. A phosphor shell was then 
successfully grown on these silica-modified hematite particles. 
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Figure 5.1 (A) Schematic illustration of the synthesis of nanoeyes (γ-
Fe2O3@SiO2@Gd2O3:Eu), SEM (B) and TEM (C) image of nanoeyes. The inserted 
figure in Figure 5.1A is the size distribution of nanoeyes. Reproduced from Ref. 125 with 
permission from the Royal Society of Chemistry. 
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Figure 5.2 SEM images of growth of Gd2O(CO3)2:Eu on spindle-shaped hematite 
nanoparticles without using an intermediate silica shell. Reproduced from Ref. 125 with 
permission from the Royal Society of Chemistry. 
500 nm
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Figure 5.3 Zeta potential of (A) hematite nanorice (+26.1 mV), (B) Gd2O(CO3)2:Eu 
(+11.1 mV), (C) silica coated hematite (-35.9 mV). Reproduced from Ref. 125 with 
permission from the Royal Society of Chemistry. 
         To increase the luminescence of the core-shell structure, and provide a hollow space 
for drug encapsulation, we etched the optically absorbing iron oxide core in oxalic acid 
solution at 60 °C for a controlled period of time. The obtained α-Fe2O3@SiO2 particles 
had a monodispersed spindle-shaped shell with a hollow space around the core and 
appeared like “nanoeyes” in TEM images. After 9.5 h of etching, the magnetic cores of 
these nanoeyes were cylinder-shaped with an average length of 150 nm and diameter of 
A
B
C
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60 nm. In addition, the length of the iron oxide core was tunable from 0 to 400 nm with 
different etching time (Figure 5.4, 5.6).  
Figure 5.4 TEM images of nanoeyes incubated in 0.5 M oxalic acid at 60 ºC for (A) 8.5 
h, (B) 9.5 h, (C) 10 h. Reproduced from Ref. 125 with permission from the Royal Society 
of Chemistry. 
           To synthesize radioluminescent particles, the silica-coated core-shell particles 
were then coated with a layer of Gd2O(CO3)2:Eu through a homogeneous precipitation 
method from gadolinium, europium nitrate. In order to convert the α-Fe2O3 to γ-Fe2O3, 
the product above was treated by H2/N2 (5%/95%) at 450 °C for 3h and calcined later in 
the air at 350 °C for 24 h. The resulting monodispersed nanoeyes (γ-
Fe2O3@SiO2@Gd2O3:Eu) had an average length of about 500 nm and diameter of 80 nm 
(Figure 5.1B). They consisted of a ~10 nm silica intermediate shell and 40 nm phosphor 
outer shell which could be distinguished in TEM images such as Figure 5.1C because of 
the different electron penetrability between the Gd2O3, SiO2, and γ-Fe2O3 core.  
            X-ray diffraction (XRD) was performed on the nanocomposite samples in order to 
investigate their structure and composition. Figure 5.5a shows the XRD pattern of the 
precursor of nanoeyes (α-Fe2O3@SiO2@Gd2O(CO3)2:Eu). The X-ray diffraction pattern 
200 nm
A B
200 nm200 nm
C
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of α-Fe2O3 is clearly distinguished from the broad peak at about 30º from the porous 
Gd2O(CO3)2:Eu. The XRD pattern of nanoeyes (Figure 5.5b) exhibits the characteristic 
diffraction peaks of cubic structure of Gd2O3. The γ-Fe2O3 core peaks in Figure 5.5b are 
indiscernibly weak because the cores have a small volume percentage and cross-section 
compared to the Gd2O3. However, the XRD pattern of γ-Fe2O3 can be readily 
distinguished under a thin shell (~10 nm) of Gd2O3:Eu (Figure 5.5c).  
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Figure 5.5 XRD patterns of (a) precursor of nanoeye (α-Fe2O3@SiO2@Gd2O(CO3)2:Eu), 
(b) nanoeye γ-Fe2O3@SiO2@Gd2O3:Eu (iron oxide core was incubated in oxalic acid for 
9.5 h), (c) nanoeye (iron oxide core was incubated in oxalic acid for 9.5 h) with thin 
Gd2O3:Eu shell (~10 nm). (▼: α- Fe2O3, ●: Gd2O3:Eu, ◆:γ-Fe2O3) Reproduced from 
Ref. 125 with permission from the Royal Society of Chemistry. 
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Magnetic and optical and properties of magnetic luminescent nanoparticles  
           In order to elucidate the magnetic properties of the nanoeyes, we synthesized 
similar shell structures with solid iron oxide cores and hollow particles with dissolved 
cores by incubation of the α-Fe2O3@SiO2 in oxalic acid for 0 h and 17 h, respectively 
(Figure 5.6). The solid-core nanorice (γ- Fe2O3@SiO2@Gd2O3:Eu) and hollow nanorice 
(SiO2@Gd2O3:Eu) both are monodispersed with a radioluminescent shell shape almost 
identical to the nanoeyes (Figure 5.7).  
Figure 5.6. TEM image of nanorice (A) and hollow nanorice (B). Reproduced from Ref. 
125 with permission from the Royal Society of Chemistry. 
 
 
200 nm 200 nm
A B
 105 
 
Figure 5.7 SEM images of nanorice (γ-Fe2O3@SiO2@Gd2O3:Eu, solid structure) (A) and 
corresponding size distribution (B). SEM images of hollow nanorice (SiO2@Gd2O3:Eu) 
(C), and corresponding size distribution (D). Reproduced from Ref. 125 with permission 
from the Royal Society of Chemistry.  
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Figure 5.8 The magnetic hysteresis loops of magnetic probes. (A) nanorice with 
maghemite as the core, (B) nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 
h), (C) nanorice with hematite as the core, and (D) hollow nanorice. Bottom inset shows 
the hysteresis loops of nanorice with hematite as the core and hollow nanorice.  Top inset 
show rapid (3 min) magnetophoretic separation of a solution of nanoeyes in a 1 cm 
pathlength cuvette. Reproduced from Ref. 125 with permission from the Royal Society of 
Chemistry. 
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            The room temperature magnetic hysteresis loops of magnetic nanorice, nanoeyes, 
and hollow nanorice are shown in Figure 5.8. The hollow nanorice (SiO2@Gd2O3:Eu) are 
paramagnetic, with minimal hysteresis and a magnetic susceptibility of 1.23×10
-4
 emu g
-1
 
Oe
-1 
and showed no sign of saturation up to applied fields of 30 kOe. From the TEM 
images (Figure 5.6) the core is approximately 13% of the volume and a similar 
percentage of the mass. The iron oxide was converted to maghemite (γ-Fe2O3) via H2 
reduction followed by oxidization in air (350 °C 24 h), and the particle colour changed 
from red with the hematite core to brownish with the maghemite core. The nanorice 
magnetization curve (Figure 5.8A) had two components, a hystertic ferrimagnetic (or 
ferromagnetic) component with a coercivity of 308 Oe and a saturation magnetization of 
~7.6 emu/g, and a paramagnetic component (linear slope at large applied fields). The 
saturation magnetization of the ferrimagnetic component is approximately 10% of the 
saturation magnetization of bulk γ-Fe2O3 (74 emu/g).
173
 These results are consistent with 
a core ~10% maghemite by weight and a shell ~90% by weight which is also consistent 
with the TEM images and ICP elemental analysis data. The hysteresis curve for nanoeye 
(Figure 5.8B) had a smaller ferrimagnetic component with a saturation magnetization of 
2.3 emu/g, which is consistent with a 3-fold reduction in weight per cent of maghemite. 
The coercivity decreased to 165 Oe likely due to the decreases in the aspect ratio of the 
iron oxide core. Although the saturation magnetization of the partially dissolved 
nanoeyes is smaller than the nanorice, the magnetization is still strong enough for rapid 
magnetophoretic separation (inset figure of Figure 5.8).  
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              In addition to magnetophoretic separation in magnetic field gradients, the 
particles are expected to align with external magnetic fields due to their magnetic shape 
anisotropy. This alignment is useful in developing sensitive and rapid immunoassays, 
viscosity sensor, and improved intracellular sensors with orientation and shape-dependent 
properties.
174-176
 For example, orientation of non-spherical particles has been shown to 
affect phagocytosis rates for adherent macrophages.
129, 177
 In addition, the ability for 
particles to rotate is useful for determining if particles are bound, while the rotation rate 
in solution is useful for measuring viscosity and viscous drag.
175
 We demonstrate that the 
magnetic nanoeyes rotate in response to a rotating external magnetic field by measuring 
the scattering signal intensity as the particles rotate in response to a changing magnetic 
field. Experimentally, we placed a solution of nanoeyes in water/glycerol 
(vwater:vglycerol=1:9) on a glass slide and observed the scattering intensity with a dark field 
microscope. The nanoeyes were orientated by an external magnetic field which rotated by 
90 º in every 3 s. As depicted in Figure 5.9, the scattering intensity was largest when the 
particles were oriented parallel to the sample plane and presented the largest scattering 
area. The scattering intensity decreased when the particles were oriented parallel to the 
optical axis. Figure 5.9C shows the magnetically modulated optical scattering by the 
nanoeyes. This rotational modulation cannot be observed for spherical particles which 
have isotropic scattering properties. 
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Figure 5.9 Schematic presentation of magnetic modulation of scattering of light (A, B) by 
nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h), (C) Intensity time 
series for nanoeyes under darkfield microscope. Reproduced from Ref. 125 with 
permission from the Royal Society of Chemistry. 
  
           In addition to magnetic rotation and separation, the nanoeyes display fluorescence 
under 480 nm excitation light and radioluminescence under X-ray excitation (Figure 
5.10). The main emission peak of the Gd2O3:Eu phosphor shell with cubic structure was 
observed at 610 nm, which corresponds to a red emission from the 
5
D0→
7
F2 Eu
3+
 
transition. The fluorescence and radioluminescence of the solid core nanorice were hardly 
detected. The luminescence quenching is likely due to inner filter effects as the 10 nm 
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silica shell spacer and hollow regions in the core would inhibit resonant energy transfer.  
Previous approaches to address this quenching problem by separating the luminescent 
shell from the absorptive core using a coating thick silica shell (>50 nm) also increase the 
particle size.
161, 165
 By contrast, the current method of partial dissolving the iron oxide 
core reduces the quenching while maintains the total nanoparticle size and volume.  We 
expect that carefully controlling dissolution time will allow optimization of the optical 
and magnetic properties.  In addition, a hollow space is formed around the iron oxide 
core in the nanoeyes which could serve to encapsulate drugs for drug delivery 
applications (See Figure 5.11). We expect that low molecular weight drugs can be loaded 
into the hollow space of the particles.  
Figure 5.10  (A) Radioluminescence spectra of nanoeyes (iron oxide core was incubated 
in oxalic acid for 9.5 h) and nanorice excited by X-ray, (B) Fluorescence spectra of 
nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h) and nanorice excited by 
480 nm light. Reproduced from Ref. 125 with permission from the Royal Society of 
Chemistry. 
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Figure 5.11 Photography of nanorice (A), nanoeyes (B), and hollow nanorice (C) without 
and with bromocresol green dye encapsulated by a ~10 nm silica coating. Samples were 
obtained after centrifuged for 15 min at 4000 rpm. Reproduced from Ref. 125 with 
permission from the Royal Society of Chemistry. 
 
           Although the hollow nanorice obtained by completely dissolving the iron oxide are 
paramagnetic, brightly luminescent, and have a large internal space for encapsulation, 
their magnetic moment is weak compared to the solid nanorice and nanoeyes, especially 
at low fields. As a result, they separate only very slowly with typical permanent magnet-
generated magnetic fields and field gradients. The nanorice particles with a solid iron 
oxide core respond rapidly to magnetic fields but display only weak fluorescence and 
negligible radioluminescence. In addition, there is not much space within the core for dye 
and drug encapsulation. By partially dissolving the iron oxide core, nanoeyes are formed 
which display magnetophoresis and radioluminescence. Their bright luminescence under 
UV (365 nm) and X-ray irradiation is shown in Figure 2.12. Compared with the UV 
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fluorescence, the X-ray luminescence of the nanoeyes provides a background-free image 
which can be used for deep tissue imaging. The hollow regions in the nanoeyes could 
also be used for indicator dye and drug encapsulation for theranostic applications. To test 
whether the pores in the Gd2O3 shell were large enough for small molecules to diffuse 
through, we incubated the nanoparticles in a solution of bromocresol blue dye, 
encapsulated the dye and particle with ~ 10 nm silica layer, and washed and separated the 
particles via centrifugation. The dye could indeed be encapsulated (see Figure 5.11), 
while a control, the solid core particles could not encapsulate dye. We are currently 
developing coatings to control the dye release rate.  
 
 
Figure 5.12 Photograph of hollow nanorice under (A) UV light (365 nm) and (B) X-ray 
luminescence. Reproduced from Ref. 125 with permission from the Royal Society of 
Chemistry. 
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Magnetic luminescent nanoparticles as T2 contrast agent 
           It is useful to have contrast agents that provide both radioluminescence and MRI 
contrast in order to validate measurements, and provide complimentary information (e.g. 
molecular information with functional XLT spectroscopy using indicators and tissue 
contrast with MRI). Our magnetic radioluminescent particles are expected to serve as T2 
and T2* contrast agents because of their strong magnetic moment in static MRI fields. 
This is consistent with recent work showing that gadolinium oxide nanoparticles have 
higher relaxivities compared with gadolinium chelates.
169, 178-179
  
 
 
Figure 5.13 T2 and T2*-weighted images of nanorice, nanoeyes (iron oxide core was 
incubated in oxalic acid for 9.5 h), and hollow nanorice at echo time of 4 ms and 1.5 ms, 
respectively. Group A: T2-weighted images of nanorice with concentration of 0.8 mg/ml, 
0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B: T2-weighted images of nanoeyes with 
concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group C: T2-
weighted images of hollow nanorice with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 
mg/ml, and 0.05 mg/ml. Group A*: T2-weighted images of nanorice with concentration 
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of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B*: T2*-weighted images of 
nanoeyes with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group 
C*: T2-weighted images of hollow nanorice with concentration of 0.8 mg/ml, 0.4 mg/ml, 
0.1 mg/ml, and 0.05 mg/ml. Reproduced from Ref. 125 with permission from the Royal 
Society of Chemistry. 
Figure 5.14 The relaxation rate curves as a function of concentration. : nanorice, : 
nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h),  hollow nanorice. 
Error bars represent the standard deviation. Reproduced from Ref. 125 with permission 
from the Royal Society of Chemistry. 
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Figure 5.15 The relaxation rate curves, 1/T2*, as a function of particle concentration. To 
calculate relaxivity, r2*, the curve is fit to a straight line for concentrations up to 0.4 
mg/mL) : nanorice, : nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h), 
 hollow nanorice. Reproduced from Ref. 125 with permission from the Royal Society 
of Chemistry. 
 
            Figure 5.13 shows T2 and T2* weighted images after 4 ms and 1.5 ms, 
respectively. The decrease with echo time was fit to an exponential in order to calculate 
the relaxation rate, R2= 1/T2 and R2* = 1/T2* at each concentration. These relaxation rates 
are shown as a function of concentration in Figure 5.14 and Figure 5.15 (see Table 5.1 for 
the molar concentration of Gd and Fe in 0.8, 0.4, 0.1, and 0.05 mg/ml of solution). The 
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curves are approximately linear, although there is some evidence of saturation at the 
highest concentration, 0.8 mg/ml. Fitting the points up to 0.4 mg/mL (2.6-3 mM), the 
relaxivities, r2 and r2* are 68.73 mM
-1
s
-1
 and 274.11 mM
-1
s
-1
 respectively for the nanorice; 
58.10 mM
-1 
s
-1
 and 120.43 mM
-1
s
-1
 for the nanoeyes, and 46.00 mM
-1
s
-1
 and 111.76 mM
-
1
s
-1
 for the hollow nanorice. The relaxivity is calculated based on the total molar 
concentration of both Gd
3+
 and Fe
3+
. For comparison with other literature we have also 
calculated r2 and r2* using the molar concentrations of just Gd
3+
 and Fe
3+
, and the total 
mass concentration in mg/mL (see Table 5.2).  For all particles, r2* is larger than r2 
because r2 includes contributions from local static field inhomogeneities caused by the 
magnetic moment of the particles. The difference between r2 and r2* may provide more 
specificity towards the contrast agents, especially for the nanorice which display a factor 
of 4 increased relaxivity. The iron oxide core significantly increased the relaxivities, with 
the solid core providing the highest relaxivity and the hollow core the least.  
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Table 5.1 ICP analysis of Gd
3+
 and Fe
3+
 in nanorice, nanoeyes, and hollow nanorice in 
0.8, 0.4, 0.1, 0.05 mg/ml of solution.The 0 value for Fe
3+
 means < 0.01 mg/L, i.e. below 
the limit of detection. Reproduced from Ref. 125 with permission from the Royal Society 
of Chemistry. 
                Weight concentration 
Type of nanoparticle 
0.8 mg/ml 0.4 mg/ml 0.1 mg/ml 0.05 mg/ml 
Nanorice Gd
3+
 4.700 mM 2.350 mM 0.588 mM 0.294 mM 
Fe
3+
 1.200 mM 0.600 mM 0.150 mM 0.075 mM 
Nanoeyes Gd
3+
 4.780 mM 2.390 mM 0.598 mM 0.299 mM 
Fe
3+
 0.730 mM 0.365 mM 0.091 mM 0.046 mM 
Hollow 
nanorice 
Gd
3+
 5.250 mM 2.626 mM 0.656 mM 0.328 mM 
Fe
3+
 0 mM 0 mM 0 mM 0 mM 
 
 
Table 5.2 r2 and r2* calculated based on molar concentration Gd
3+
, Fe
3+
, Gd
3+
+Fe
3+
, and 
weight concentration of particles. Reproduced from Ref. 125 with permission from the 
Royal Society of Chemistry. 
                                                     Relaxivity 
 
Type of nanoparticle 
 
                   r2 
 
                  r2* 
 
 
     Nanorice 
Weight concentration  514 ml mg
-1
s
-1
 2029 ml mg
-1
s
-1
 
Molar concentration (Gd
3+
) 86.28 mM
-1
s
-1
 344.10 mM
-1
s
-1
 
Molar concentration (Fe
3+
) 337.92 mM
-1
s
-1
 1347.71 mM
-1
s
-1
 
Molar concentration (Gd
3+
+Fe
3+
) 68.73 mM
-1
s
-1
 274.11 mM
-1
s
-1
 
 
 
    Nanoeyes 
Weight concentration  454 ml mg
-1
s
-1
 847 ml mg
-1
s
-1
 
Molar concentration (Gd
3+
) 66.97 mM
-1
s
-1
 138.82 mM
-1
s
-1
 
Molar concentration (Fe
3+
) 438.54 mM
-1
s
-1
 909.00 mM
-1
s
-1
 
Molar concentration (Gd
3+
+Fe
3+
) 58.10 mM
-1
s
-1
 120.43 mM
-1
s
-1
 
Hollow 
nanorice 
Weight concentration  322 ml mg
-1
s
-1
 701 ml mg
-1
s
-1
 
Molar concentration (Gd
3+
) 46.00 mM
-1
s
-1
 111.76 mM
-1
s
-1
 
               Previous work showed that ultrasmall Gd2O3 nanoparticles (1~10 nm)
139-142
 and 
hollow nanosparticles with thin Gd2O3 shell (~10 nm)
143
 served as good T1 contrast 
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agents and moderate T2 contrast agents. In contrast, our spindle-shaped nanoparticles 
with a ~40 nm Gd2O3:Eu shell worked better as a T2 contrast agents. This may be due to 
low water exchange efficiency inside of the porous Gd2O3 nanoparticles, which is 
consistent with earlier work by using the porous Gd2O3 nanoparticles (~200 nm in 
diameter).
143
 Compared to FDA-approved iron oxide nanoparticle contrast agents such as 
Ferumoxtran (Resovist®, 65 mM
-1
s
-1
),   cross-linked iron oxide particle (CLIO-Tat, 62 
mM
-1
s
-1
), and water soluble iron oxide (WSIO, 78 mM
-1
s
-1
), our nanorice, nanoeyes, and 
hollow nanorice had similar T2 relaxivities.
147-150
 However, these T2 relaxivities were 
several times higher than typical gadolinium chelates (Gd-DTPA, 4.9 mM
-1
s
-1
)
144
 and 
Gd2O3 nanoparticles (14.1~16.9 mM
-1
s
-1
).
144-146
 Most importantly, the contrast is 
sufficient for many drug delivery applications. For example, 5~10 mg/mL is a typical 
magnetic particle concentration in tumors for  magnetic hyperthermia,
180
  while our 
particles have several times faster relaxation rates than the gel even at the lowest 
concentrations of 50 µg/mL (R2 is 37.7 s
-1
 for the nanorice, 29.3 s
-1
 for nanoeyes, and 
20.0 s
-1
 for the hollow nanorice). 
 
Nanoparticle Cytotoxicity Assay 
           Previous studies toxicity of ~80 nm iron oxide nanoparticles found no acute or 
subacute toxic effects by histologic or serologic studies in rats or beagle dogs which 
received a total of 3 mmol Fe/kg.
181
 In order to study the potential cytotoxicity of the rare 
earth elements in the magnetic imaging probes (nanorice, nanoeyes, and hollow nanorice), 
an in vitro cytotoxicity test of hollow nanorice was performed on MCF-7 breast cancer 
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cells (Figure 5.16). The viability of the untreated cells was set as 100% in order to 
calculate the viability of the cells treated by different concentration of X-ray phosphors. 
Cell viability is not significantly affected by the Gd2O3:Eu nanoparticles up to 
concentration of at least 250 µg/ml (24 hr exposure).  
 
Figure 5.16 Cytotoxicity test for hollow nanorice (Gd2O3:Eu). Reproduced from Ref. 125 with 
permission from the Royal Society of Chemistry. 
Conclusion 
              We successfully prepared magnetic luminescent nanoparticles using silica coated 
hematite as a template. The silica coating plays a critical role on the growth of phosphor 
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shell on the surface of the nanocores. After synthesis, the cores were made magnetic via 
high temperature reduction in H2 and oxidization in air. The magnetic core size could be 
controlled while preserving the luminescent shell by dissolving the core in oxalic acid. 
Intermediate core sizes displayed both magnetic and luminescent properties. These novel 
magnetic luminescent nanoparticles are advantageous because they allow for magnetic 
separation and multimodal imaging with MRI, fluorescence and radioluminescence. We 
expect that such nanocomposites, combining the advantages of magnetism and 
luminescence, will find extensive applications in drug delivery and bioimaging.  For 
example, the hollow structure in the partially dissolved iron oxide phosphor can be 
loaded with small dyes and drug molecules.  Our synthesis technique is attractive because 
multifunctional particles can be made by coating the core templates with multiple layers 
of materials, each with a controlled thickness and composition. Different sizes, shapes 
(spherical and non-spherical), and structures (hollow and non-hollow) can be obtained by 
varying the shape and size of the hematite templates. Future work will study the effect of 
size and shape on magnetic, luminescent, and bio-distribution properties.   
Experimental Section 
Materials 
             Iron (III) chloride anhydrous and tetraethoxysilane (TEOS) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Gadolinium Nitrate, Europium nitrate, 
potassium dihydrogen phosphate, and sulfur powder (99.5%) were purchased from 
obtained from Alfa Aesar (Ward Hill, MA).  Ethanol (anhydrous, denatured), urea, 
oxalic acid, ammonium hydroxide, and nitric acid were obtained from BDH 
 121 
Chemicals Ltd (Poole, Dorset, UK). Deionized (DI) water was purchased from EMD 
Chemicals Inc. (Gibbstown, NJ, USA). Polyvinylpyrrolidone (PVP K-30, MW 
40,000) was purchased from Spectrum Chemicals (Gardena, CA). Agarose (melting 
point 88±1 ºC) was purchased from Shelton Scientific (Peosta, IA). All chemicals 
were used as received without further purification.   
Synthesis of spindle-shaped hematite particle 
               Monodispersed spindle-shaped hematite nanoparticles with controllable aspect 
ratios were fabricated were prepared according to the method described by Ozaki and 
coworkers
182
. Typically, 100 ml of aqueous solution containing 2.0×10
-2
 M FeCl3 and 
4.0×10
-4
 M KH2PO4 were aged at 100 °C for 72 hours. The resulting precipitate was 
centrifuged and washed three times with water.  
Synthesis of spindle-shaped hematite particle with silica shell 
               To obtain momodispersed hematite-silica core-shell nanoparticles, the PVP 
assisted coating method was used.
183
 The spindle-shaped hematite particles synthesized 
above were dispersed ultrasonically to a 80 ml solution containing PVP (0.6 g), water (6 
ml), and ethanol (74 ml). The suspension was stirred using a magnetic stir bar at room 
temperature and a solution of TEOS (270 µl) in 20 ml ethanol was added, followed by 4 
ml of ammonia hydroxide. After 3h, the reaction mixture was precipitated by centrifuging 
at 4000 rpm for 16 min. The particles were washed three times with ethanol and 
centrifuged to collect the product.   
Synthesis of spindle-shaped magnetic phosphors 
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                The products above were suspended in 180 ml distilled water with 1.8 g PVP 
and 11.34 g oxalic acid (0.5 M) incubated at 60 °C for certain time. The hematite 
partially dissolved particles were collected by centrifugation and rinsed with DI water 
twice. The obtained particles were resuspended with 3 ml Gd(NO3)3, 1.5 ml Eu(NO3)3 
(80 mM), and 1.8 g PVP in pure water to form 300 ml of solution. 18 g of urea was added 
to the solution and the solution was maintained at 80 °C for 90 min. The precursor of 
magnetic phosphor was collected by centrifugation. The precursor of spindle-shaped 
precursor was calcined in a furnace at 600 °C for 60 min. The powder was then 
transferred to a tube furnace with a H2/N2 (5%/95%) flow at 450 °C for 3h. After that, the 
sample was calcined in the tube furnace at 350 °C for 24 h. 
Preparing nanocomposites for MR Imaging. 
              T2 and T2* MR measurements were acquired for the spindle-shaped γ-
Fe2O3@SiO2@Gd2O3:Eu particles at a series of concentrations (0.8 mg/ml, 0.4 mg/ml, 
0.1 mg/ml, and 0.05 mg/ml).  The particles were dispersed in 0.5% agarose gel at 80 °C 
and cooled to room temperature in NRM tubes to set the gel.  The gel prevented settling 
and aggregation allowing MRI imaging several days after preparation.  
Cell viability test 
                MCF-7 breast cancer cells were seeded at a density of 10,000 cells/well in a 96-
well plate.  Cells were stored at 37 °C at 5% CO2 and attached to the plate overnight.  
Nanoparticles were suspended in media, sonicated for 10 minutes to disperse, and diluted 
to 250, 100, 50, and 10 µg/ml.  Media was removed from wells and fresh media or 
nanoparticle in media was added to each well. Five repeats were done for each 
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concentration.  Nanoparticles were incubated with cells overnight and the next day a 
Presto Blue assay (Life Technologies) was performed. Media was removed and 100 µl of 
a 1:9 ratio Presto Blue in culture media was added to each well.  Cells were incubated at 
37 °C and 5% CO2 for 45 minutes. Fluorescent intensity was taken with a plate reader 
with an excitation wavelength of 560 nm and an emission wavelength of 590 nm. 
Fluorescent intensity for each concentration of nanoparticle was normalized as a 
percentage of the fluorescent intensity of the control cells. Percent viability averages 
were plotted with error bars of one standard deviation.   
Intrumentation 
                Transmission and scanning electron microscopy (TEM) were performed on a 
H9500 operated at 300 kV and HD2000 microscope operated at 100 kV, respectively. An 
X-ray diffractometer (Rigaku; MiniFlex, Cu Kα) was used to characterize the XRD 
pattern of the magnetic phosphors. For fluorescence spectra, 480 nm light was used to 
excite the phosphors.  
               To measure radioluminescence, X-ray was generated by a mini X-ray tube 
(Amptek Inc. MA, USA), the X-ray tube was operated with tube voltage of 40 kV and 
tube current of 99 µA. The sample was mounted on a Leica Microscope (Leica DMI 
5000M, Wetzlar, Germany) equipped with a DeltaNu DNS 300 spectrometer (Intevac-
DeltaNu, Laramie, WY USA) with a 150 lines/mm grating blazed at 500 nm.  
                The Zeta-potential of the nanoparticles was determined using a Malvern 
Instruments Zetasizer Nano ZS with a 633 nm He-Ne laser. Prior to the experiment, the 
particles were diluted in distilled water (0.1 mg/ml). Magnetization measurements were 
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performed at the designated temperature using vibrating sample magnetometer (VSM) 
option of physical property measurement system (PPMS, Quantum Design, USA), with 
the applied magnetic field sweeping between +/- 3.0 Tesla at a rate of 50 Oe/sec. 
Determination of the gadolinium and iron content in a sample was performed by 
inductively coupled plasma (ICP)- (Optima 3100 RL; Perkin-Elmer). 
                In order to magnetically modulate the optical scattering from the magnetic 
luminescent particles, the particles were oriented and rotated in a magnetic field. A 
permanent magnet (NdBFe, 1” in diameter, 3” in length, magnetized through its 
diameter) was attached to a stepper motor and controlled by motion control software (Si 
Programmer; Applied Motion Products, Watsonville, CV). Every 3s, the permanent 
magnet was rotated 90º, first clockwise and then anticlockwise. 
                 All MRI experiments were performed on a Varian 4.7T horizontal bore 
imaging system (Agilent Inc, Santa Clara, CA).  Samples, contained in 5 mm NMR 
tubes, were placed in a 63 mm inner diameter quadrature RF coil for imaging. MRI 
gradient echo scout images were collected in all three imaging planes (axial, coronal, and 
sagittal) for subsequent image planning, with repetition time (TR) = 100 ms, echo time 
(TE) = 4 ms, number of slices =20, slice thickness =2, matrix size 128×128, field of view 
(FOV) = 40 mm×40 mm, number of acquisitions (NEX) =2.   Relaxivity measurements 
were then collected on a single 2 mm thick imaging slice, approximately perpendicular to 
the long axis of the NMR tubes. The single slice, with FOV = 36 mm×36 mm, was 
imaged using a T2-weighted multi-spin echo imaging sequence with TR = 3000, NEX = 
10, echo spacing = 4ms, number of echoes = 10, and 128 x 128 matrix.  T2*-weighted 
 125 
images were collected using a gradient echo imaging sequence with TR = 500 ms, flip = 
20°, 128×128 matrix, NEX = 10, and echo times = [1.5, 3, 4.5, 9, 15 ms]. Following data 
collection, images were analyzed using Matlab 2011a (The Mathworks, Inc., Natick, 
MA). Regions of interest (ROI’s), encompassing approximately 70-80 voxels, were 
manually drawn in each sample, and the signals from those voxels averaged to obtain a 
mean signal for each sample. The same ROI was used to calculate the mean signal of the 
sample across all echo times.   
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                                                      CHAPTER SIX 
VI. CONCLUSIONS AND FUTURE DERECTIONS   
             In chapter II and III, we developed a novel technique (XEOL) for in situ 
chemical imaging through tissue with high spatial resolution. When the X-ray excited 
luminescence combines with suitable chemical sensing dyes (fluorescent and colorimetric 
indicators), a background-free radioluminescence based pH sensor was fabricated. The 
high spatial resolution (0.30 mm) through 10 mm of chicken breast was demonstrated by 
detecting a two-color X-ray phosphor film.  We then extended the XEOL technique to 
imaging silver dissolution under 10 mm pork where it also offers a combination of high 
spatial resolution (limited by the X-ray beam width) and high sensitivity optical detection. 
Fluorescent and colorimetric indicators and stains are widely used for histology and 
biomedical research because of their high sensitivity and specificity for a wide variety of 
analytes. XEOL indicators combine the advantages of optical indicators with high 
resolution, low background imaging from scanning X-ray excitation. A particularly 
attractive application is imaging chemical (e.g biofilm) and mechanical changes on 
implanted medical devices, which can become infected. Many analytes can be measured 
(e.g. pH, silver metal dissolution, oxygen, and protease activity). Relatively thick 
phosphor films may be used to improve X-ray luminescence capture, and signal strength 
especially at high energies. The two dimensional nature of the surfaces simplifies and 
speeds up imaging. An important challenge will be to minimize the spectral distortion 
caused by wavelength dependent tissue scattering and absorption, especially for deeply 
implanted devices. Several techniques are possible, including calculation of spectral 
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ratios using closely spaced spectral peaks, use of spectral reference regions near to the 
sensor region, and lifetime-based imaging. Another technical challenge will be 
integrating the sensor film onto the implanted device while minimizing delamination, 
abrasion, and reducing bacterial adhesion. After sensor development, the next step will be 
integration of sensing with active components such as combining magnetic or 
photothermal hyperthermia and drug release with local pH sensors to monitor the effect 
of therapies on local biofilm chemistry.  
                 In addition to chemical analysis on surfaces, XEOL can be used for three 
dimensional tomography similar to X-ray luminescence tomography (XLT) and limited-
angle XLT. For example, our group has developed hollow nanoparticles with 
encapsulated magnetic iron oxide nanoparticles. The luminescence is quenched by iron 
oxide in the core and increases as the iron oxide is etched.
125
 We have also encapsulated 
indicator dyes and are studying leaching rate as a function of pH. In future we expect that 
these types of sensors will be useful for local drug delivery while measuring the amount 
of drug delivered in time. Additional sensors with unique optical emission spectra can be 
used for simultaneously studying changes in cellular chemistry such as endosomal pH 
changes upon apoptosis. Such in situ sensors will be useful for optimizing therapeutic 
agents and monitoring effectiveness.  
              Future work involves using chemical indicator dyes for oxygen and other 
analytes, using narrower X-ray beams and more sensitive detection optics for two 
dimensional chemical imaging and tomography, and developing a portable imaging 
system.  Two dimensional chemical imaging will be especially useful for measuring 
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chemical changes on a surface, such as in situ detection of acidosis, hypoxia, and 
hydroxyapatite degradation on implanted devices with bacterial colonies. Phosphoresent 
lifetime measurements are alternative approaches which do not depend on scattering or 
absorption. We may also measure the lifetime of long-lived Oxygen sensing molecules 
such as Ru(dpp) or platinum complexes. These dyes are quenched by oxygen and serve 
as oxygen sensors. We can also use phosphors with relatively fast decay time to 
distinguish the lifetime of the chemical indicator from the phosphors or use long lifetime 
phosphors and measure the quenching lifetime caused by adsorbed acceptor molecules or 
plasmonic nanoparticles.  Recent developments in X-ray imaging and contrast agents are 
opening up new opportunities for high-resolution functional imaging. In all cases, a key 
advantage of XEOL is that high resolution images can be generated because X-rays can 
penetrate deeply through tissue and have relatively low scattering coefficients. The 
images can also be co-registered with structural information from X-ray attenuation 
imaging and integrated with other imaging techniques such as diffuse optical 
fluorescence tomography and MRI. The main disadvantage of X-ray imaging, however, 
is that large X-ray doses cause short term tissue damage/radiation sickness, and increase 
the long term risk of developing cancer.
47, 184-185
 Consequently, the challenge will be to 
maximize the analytical sensitivity, specificity, image resolution, and acquisition rate 
while minimizing the X-ray dose, contrast concentration, and contrast toxicity. The use of 
up-conversion nanophosphors which are able to emit visible light under near infrared 
light excitation is alterative approach to address the safety concern of X-ray but at cost of 
spatial resolution.
186-187
 
 129 
         A wide variety of contrast agents with unique spectra have been developed for 
phosphor film applications and these can be used for X-ray luminescence tomography 
contrast (see Table. 1). New X-ray excited luminescent nanoparticles are expected to 
explored to meet the application of XEOL. High optical collection efficiencies are also 
required using large area photodetectors and potentially integrating sphere optics. In 
limited angle configurations the X-ray luminescence tomography images can be acquired 
rapidly, although with some loss of resolution along one dimension.
56
 We expect that 
continuing development of phosphor nanomaterials, targeting moieties, and 
instrumentation will greatly expand the utility of X-ray luminescence tomography. Many 
of the phosphor materials also have large magnetic permeability and serve as effective 
MRI contrast agents.
125
 
             In Chapter IV, we present a flexible template-directed method to produce non-
sphrical radioluminescent nanocapsules for an anticancer drug (DOX) carrier, monitor 
release kinetics, and magnetic drug carrier. The hollow radioluminescence nanocapsules 
demonstrate a multifunctional platform with an X-ray excited optical luminescence 
(XEOL) spectrum that changes during drug release. These nanocapsules are also 
paramagnetic, allowing them to be used as MRI imaging agents. The future work will 
focus on the study of toxicity of DOX loaded nanocapsules, pH dependent drug release in 
vivo, target DOX loaded capsules to tumors, and measure in situ release rates and tumor 
growth for various nanocapsule sizes, shapes, and surface chemistries. In order to reduce 
required X-ray dose to capsule enough X-ray excited luminescence, more studies will 
focus on enhance the luminescence of anophosphors. Some templates such as carbon 
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nanospheres which can be decomposed in the synthesis of nanophosphors is one of the 
approaches to simplify the process of nanocarrier synthesis. Some flux (Na2CO3, NaF, 
etc.) used in  traditional solid reaction can successfully improve the luminescence of X-
ray phosphors. However, the size (> 1 μm) of phosphors are not suitable for molecular 
imaging or drug delivery. Novel method based on the use of flux are promising to obtain 
ultrabright X-ray phosphor in nanosize. Combination of up conversion phosphors which 
can be excited by near infrared and emit visible light with X-ray phosphor is alternative 
approach to reduce the dose of X-ray used to locate the drug nanocarrier. 
              Chapter V provides a partially etching method to fabricated magnetic 
luminescent nanocapsules.  These magnetic capsules can serve good contrast agent for 
XEOL, T2 weighted MRI, and magnetic nanocarriers. In the future, we plan to target the 
tumor in vivo by applying magnetic field on the drug loaded magnetic capsules. Novel 
method should also be explored to improve the luminescence intensity such as the use of 
flux to improve the X-ray excited luminescence or coating brighter up-conversion 
phosphor on iron oxide nancores. In order to increase the saturated magnetization of the 
nanocarriers, fabricating stronger magnetic materials such as pure iron nanoparticles need 
be studied because these materials shows ultra-high saturated magnetization (212 
emu/g)
188
 and relaxivity (330 mM
-1
s
-1
) for T2-weighted magnetic resonance imaging 
189
.  
            Overall, XEOL-based multifunctional X-ray nanophosphors are highly 
promising for rapid and sensitive chemical analysis in tissue or the surface of implanted 
medical devices. With further improvements in instrumentation and contrast agents, we 
expect a bright future for high resolution molecular imaging with X-ray nanophosphors.   
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